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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
Vaccines have prevented at least two million deaths worldwide in 2003 alone, yet the 
World Health Organization has estimated that at least 27 millions infants go without 
proper immunizations, making them susceptible to diseases easily prevented 1.  Current 
alum-based adjuvants (which are molecules that enhance immune response) have been 
shown to be weak to poor at inducing an immune response; in addition, often more than 
one dose is needed for protection.  The use of Freund’s complete adjuvant and the 
addition of lipopolysaccharide have both received much attention as inclusions in 
carriers, yet both have been proven to be toxic in humans 2,3.  Clearly there is a need to 
develop new adjuvants for vaccine delivery that are easy to manufacture and non-toxic.  
Biodegradable polymeric systems, in particular poly(D,L-lactide-co-glycolide) (PLGA) 
and polyanhydrides, have received much attention as potential vaccine carriers.  These 
polymers have the ability to degrade by hydrolysis into their non-toxic monomeric units, 
lactic and glycolic acids and dicarboxylic acids, respectively.  Parenteral delivery of these 
polymers can be achieved by fabricating microspheres, which allows the drug to be 
released over a desired period of time; due to the degradation of the polymers, there is no 
need to remove the device once the drug has been delivered.  However, the relatively 
acidity (due to dissolution of the lactic and glycolic acid monomers) and the bulk eroding 
properties of PLGA may be detrimental to the stability of encapsulated proteins, causing 
denaturation and even irreversible aggregation 4,5.  On the other hand, recent studies with 
polyanhydrides 6,7 have shown that the surface erodible feature of these polymers can be 
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combined with less hydrophobic monomers to create a new class of amphiphilic materials 
that are preferable for a wide range of protein and vaccine delivery applications.   
 
Polyanhydrides are currently being studied as possible alternatives to alum-based 
adjuvants 8. In addition, polyanhydrides are surface eroding, which allows the antigen to 
be released over a predictable period of time.  This eliminates the need to administer 
subsequent doses of antigen in the case of vaccines 9.  Because degradation varies 
depending on the chemistry and structure, a tailored release rate can be achieved 10.  The 
surface-eroding properties of polyanhydrides, combined with their relative 
hydrophobicity, implies that proteins are less likely to undergo moisture-induced 
aggregation, thereby retaining their stability 11,12.  Polyanhydrides have been proven to be 
compatible in vivo, as shown by the polyanhydride-comprised Gliadel® wafer.  
Approved by the FDA in 1996, Gliadel® is used to deliver bis-chloroethylnitrosourea to 
treat a form of brain cancer.  In addition, an in vivo study demonstrated the 
immunomodulatory properties of tetanus toxoid-loaded polyanhydride microspheres; by 
changing the chemistry, a TH0 (balanced) immune response was attained 8.  Protection 
from diseases such as cancer require induction of TH1 (cell-mediated) immune responses; 
traditional alum-based vaccines enhance TH2 (humoral) responses 13. 
 
The overall objective of the research therein was to demonstrate the effect of polymer 
chemistry on release kinetics, protein stability, and immune activation.  It is anticipated 
that application of the results of these studies will lead to rational design of carriers for 
specific therapeutic modalities.  Polyanhydrides of various chemistries based on the 
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monomers of sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were investigated in course of this research; 
these polymers are shown in Figure 1.1.  Chapter 2 summarizes literature regarding 
polyanhydride synthesis and characterization, microsphere fabrication and 
characterization, mechanisms of immune response, adjuvants and vaccines, and novel 
therapies using polymers.  Chapter 3 lists the goals of the research project. Chapter 4 
details the release kinetics of protein-loaded polyanhydride microspheres and analyzes 
the protein’s primary structure and activity once released from the microspheres.  Chapter 
5 describes the effects of polyanhydride chemistry on the activation of bone marrow 
derived dendritic cells as measured by studying changes in cell surface marker 
expression.  Finally, Chapter 6 summarizes the work of the previous two chapters, and 
gives a direction as to where the work conducted will lead. 
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Figure 1.1 – Chemical structures of polymers used, from top, left to right: poly (sebacic 
acid), poly (1,6-bis(p-carboxyphenoxy)hexane), and poly (1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane), where n represents the number of repeating monomer units. 
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
2.1 Summary 
This chapter discusses the literature that is relevant for the polyanhydride work described 
in this thesis.  Section 2.2 provides an in-depth discussion of polyanhydrides, focusing on 
the chemistry, synthesis, characterization, and what sets polyanhydrides from other 
biodegradable polymers used in drug delivery.  Section 2.3 details microsphere 
fabrication and characterization.  A brief introduction to immunology, mainly directed at 
dendritic cells, innate versus adaptive immunity, and the major histocompatibility 
complex, is given in Section 2.4.   Adjuvants and vaccines are discussed in Section 2.5.  
Section 2.6 summarizes the current state-of-the-art and raises unsolved issues in this area, 
some of which are the subject of this thesis. 
 
2.2 Polyanhydrides 
2.2.1 History 
In 1909, Bucher and Slade documented the first synthesis of polyanhydrides upon heating 
isophthalic and terephthalic acid with acetic anhydride .  Their work led to the 
investigation of polyanhydrides as textiles by Hill and Carothers in the 1930s; they soon 
learned that this class of polymers was not suited for such an application due to the 
polymers’ capabilities to hydrolytically degrade.  Hill and Carothers also discovered new 
properties of polyanhydrides, such as their instability at high temperatures, which causes 
them to transform into cyclic dimers and polymeric rings .  It was not until the 1980s 
1
2-4
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that a connection was made between polyanhydrides, due to their degradation properties 
and biomedical applications.
 
2.2.2 Structures 
Polyanhydrides can be grouped into different classes, based on the properties of their 
constituent monomers.  Varying the chemistry of the polyanhydride backbone can 
considerably change the properties of the resulting polymer, such as solubility, 
mechanical strength, crystallinity, and degradation rate.  While there are literally 
hundreds of polyanhydride structures synthesized, two chemistries are predominantly 
used in the medical field: aliphatic and aromatic. 
 
2.2.2.1 Aliphatic 
Poly(sebacic anhydride) was the first aliphatic polyanhydride synthesized by Hill and 
Carothers in 1932 .  Aliphatic polyanhydrides are crystalline, brittle, typically melt at 
temperatures below 100°C, and are soluble in chlorinated hydrocarbons.  These 
polyanhydrides are known to be sensitive to hydrolysis, and degrade and are eliminated 
from the body within weeks .  To fabricate a slower degrading aliphatic polyanhydride, 
the alkyl chain length of the monomer can be increased, thereby increasing the 
hydrophobicity of the polymer and lengthening the degradation time of the polymer .  
Aliphatic polyanhydrides are usually prepared by melt condensation reactions, as their 
diacids are typically not affected by heat .  Typical diacids used for aliphatic 
polyanhydrides include adipic acid, dodecanoic acid, fumaric acid, sebacic acid, and fatty 
acid dimers .   
3,4
5
5
6
7
7 
 
2.2.2.2 Aromatic 
Aromatic polyanhydrides of isophthalic and terephthalic acid were first synthesized by 
Bucher and Slade in 1909 .   Typical diacids used include phthalic acid and several types 
of carboxyphenoxyalkanes .  Aromatic polyanhydrides are less soluble in common 
organic solvents and characteristically more hydrophobic than aliphatic, melt at 
temperatures above 200°C, degrade over time spans of years, and possess fairly high 
strength and stability .  These properties make pure aromatics difficult to process into 
films or microspheres, since these techniques usually require lower temperatures to melt 
at or for the polymer to be easily solubilized.  In order to overcome these barriers, 
aromatics are typically copolymerized with other polyanhydrides, such as aliphatic 
diacids; the copolymers tend to take on the characteristic properties of their aliphatic 
portion . 
1
7
8,9
10
 
2.2.2.3 Novel polyanhydrides 
The hydrophobic chemistry of polyanhydrides help to prevent water-induced covalent 
aggregation of proteins since water penetration into the bulk is negligible; however, when 
incorporated with a protein, noncovalent aggregation may result due to hydrophobic 
interactions .  By incorporating a hydrophilic oligomeric ethylene glycol unit, such as 
triethylene glycol, into the backbone of a hydrophobic aromatic polymer, both covalent 
and noncovalent aggregation can be controlled .  The resulting amphiphilic polymer is 
also closer to bulk-eroding, a novel characteristic for the normally surface-eroding 
polyanhydrides.  However, upon copolymerizing with an aromatic polyanhydride, the 
11,12
13
8 
 
surface-eroding properties can be regained, providing a controlled release profile 
characteristic . 13
 
2.2.2.4 Other 
Many other polyanhydride structures exist, each with their own characteristics.  The 
crystalline unsaturated polyanhydride homopolymers are insoluble in common organic 
solvents; to solubilize in chlorinated hydrocarbons, unsaturated polyanhydrides are 
copolymerized with aliphatic diacids, which also makes them less crystalline .  
Crosslinked polyanhydrides are used for situations where a greater mechanical strength is 
required, as most other polyanhydrides are rather brittle and cannot be used in load-
bearing applications .  The copolymerization with imides can enhance the tensile 
strength and thermal resistance of polyanhydrides, making them ideal for applications 
such as sutures .  Fatty acid-based polyanhydrides based on oleic acid and eurucic acid 
are viscous liquids; typically, these polymers are copolymerized with an aliphatic 
polyanhydride such as sebacic acid to solidify  . 
14
14
15
16
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Aliphatic polyanhydrides
STRUCTURE EXAMPLES
x = 4  Poly(adipic acid)
x = 8  Poly(sebacic acid)
x = 10 Poly(dodecanedioic acid)
Aromatic polyanhydrides
x = 1  Poly[1-bis(p-carboxyphenoxy)methane]
x = 3  Poly[1,3-bis(p-carboxyphenoxy)propane]
x = 6  Poly[1,6-bis(p-carboxyphenoxy)hexane]
para-  Poly(terephthalic acid)
meta- Poly(isophthalic acid)
R group from:
Novel polyanhydrides
Poly[1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane]
 
Figure 2.2 – Common structures of polyanhydrides used in drug delivery applications
 
2.2.3 Synthesis 
Polyanhydrides can be prepared through a variety of techniques, including melt 
condensation in conjunction with acetic anhydride, solution polymerization, dehydrative 
coupling, interfacial condensation, and ring-opening polymerization. 
 
2.2.3.1 Melt polycondensation 
The conversion of dicarboxylic acids into polyanhydrides takes place in two steps, the 
first being the reaction of the monomers with excess acetic anhydride by reflux.  By 
heating the aforementioned prepolymer under vacuum at a high temperature to eliminate 
the acetic anhydride, the subsequent polyanhydride is formed, with a molecular weight of 
100 to 1000 16,17.  Further studies indicated that polymerization at 180°C for 90 minutes, 
with a 10-4 mmHg vacuum and dry ice/acetone trap, provided the optimal molecular 
weight.  Additionally, it was found that increasing the reaction time or reaction 
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temperature did not increase the molecular weight of the polymer 18.  The use of 
coordination catalysts, such as cadmium acetate, earth metal oxides, orZnEt2·H2O, could 
be employed to achieve even higher molecular weights with less reaction time 19.  The 
resulting polyanhydride is dissolved in an organic solvent, and precipitated in hexane.   
OH
O
OH
O
R O
O O
O R O
O O O O
m
 
O R O
O O O O
n
 
+
REFLUX
180 C, 90 min
10-4 mm Hg
 
Figure 2.3 – Schematic of melt polycondensation reaction 
 
2.2.3.2 Solution polymerization 
Solution polymerization employs a Schotten-Baumann condensation reaction to 
synthesize polyanhydrides.  It is advantageous to use this method over melt condensation 
when synthesizing heat-sensitive monomers, due to possible charring at the high reaction 
temperature or the high melting point of the subsequent polymer.  However, the diacid 
halide monomer needs to be of utmost purity in order to use this technique 20.  Yoda and 
Mikaye were the first to develop this technique in 1959; Subramanyam and Pinkus 
further developed this method with the inclusion of an acid acceptor 21,22.   Briefly, a 
dehydrochlorination reaction occurs when a diacid halide is added to an ice-cold solution 
of a dicarboxylic acid, in a dry nitrogen environment and in the presence of an organic 
solvent, such as benzene, ethyl ether, or chloroform.  Polycondensation was only 
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facilitated in the presence of an acid acceptor, such as triethylamine.  The key to 
obtaining high molecular weight polymers is to add the diacid dropwise to the diacid 
halide solution to allow full contact, and not the reverse; otherwise an ionic salt is formed 
as a result of the triethylamine reacting with the terephthaloyl chloride complexes 21.  
High molecular weight polymers are desirable to allow for control over the degradation 
process of polyanhydrides. 
OH
O
OH
O
R Cl R' Cl
O O
* R O R' O *
O O O O
n
 
+
BASE
+ BASE * HCl
 
Figure 2.4 – Schematic of solution polymerization reaction 
 
2.2.3.3 Dehydrative coupling 
Dehydrative coupling, like solution polymerization, is an alternative to melt-
polycondensation reactions for monomers that are thermolabile 9.  This method utilizes a 
dehydrative coupling agent, such as N’N-bis(2-oxo-3-oxazolidinyl)phosphonic chloride, 
in conjunction with a dicarboxylic acid monomer to produce the polymer 23.  Other 
coupling agents include phosgene and diphosgene; the use of an acid acceptor such as 
poly(4-vinyl pyridine) has been shown to yield higher molecular weight polymers 24.  
Dehydrative coupling is considered the simplest polymerization technique, due to its one 
step protocol and no need for an intermediate, prepolymer forming step.  However, many 
drawbacks exist, such as the need for fresh catalyst for each reaction and the possible 
contamination of the polymer with catalyst by-products. In order to rid the polymer of the 
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catalyst derivatives, a washing step with a protic solvent is needed, which can potentially 
lead to hydrolysis of the polymer 23. 
 
2.2.3.4 Ring-opening polymerization 
Hill and Carothers first studied the ring-opening polymerization mechanism with adipic 
acid and acetic anhydride under a  reaction similar to melt polycondensation 2.  Upon 
noting the low molecular weight of the polymer, they decided to subject this polymer (α-
anhydride) to elevated temperatures to see if it would improve the molecular weight.  
This resulted in a distillate of cyclic monomers and dimers (β-anhydride), and a much 
higher molecular weight polymer remaining in the still (ω-anhydride).  Upon standing, 
the cyclic monomers and dimers converted into cyclic polymers (γ-anhydride), with a 
molecular weight of 5000; the schematic of this process is shown in Figure 2-4.  They 
later extended their studies to include a larger number of diacids, which included HOOC-
(CH2)n-COOH,  with n being 4-12 or 16 3,4.   
OH CH2 OH
OO
n
 
α-anhydride
(linear polymer)
β-anhydride
(cyclic dimer)
+ ω-anhydride
(residue)
γ-anhydride
(cyclic)  
Figure 2.5 – Schematic of ring opening polymerization reaction 
Albertsson and Lundmark 25 demonstrated the formation of poly(adipic anhydride) from 
oxepane-2,7-dione in the presence of stannous 2-ethylhexanoate.  The preparation of this 
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cycle polyanhydride was completed in two steps, the first being the reflux of adipic acid 
with acetic anhydride and, consequently, the removal of acetic anhydride with a zinc 
chloride hydrate catalyst to form oxepane-2,7-dione monomer.  The second step involved 
melt polymerization with a stannous 2 ethylhexanoate inhibitor; the pair also tried other 
inhibitors such as cationic (AlCl3 or BF3·(C2H5)2O) and anionic (CH3COO-K+ or NaH) 
categories, as well as other coordination-type inhibitors (dibutylinoxide) 25,26.  First 
attempts to polymerize (80°C for 5 hours) resulted in a low molecular weight polymer.  
Later efforts produced a polyanhydride with a slightly higher molecular weight after 
improving upon the monomer-initiator ratio and the optimal polymerization time (two 
hours) 26. 
 
2.2.4  Characterization 
Many characterization techniques are employed to analyze polyanhydrides and confirm 
their purity, based on chemical structure, crystallinity, molecular weight, and thermal 
properties.  These techniques include Fourier transform infrared spectroscopy (FTIR), 
Fourier transform Raman spectroscopy (FTRS), proton nuclear magnetic resonance 
spectroscopy (1H-NMR), gel permeation chromatography (GPC), differential scanning 
calorimetry (DSC), and X-ray diffraction. 
 
Fourier transform infrared spectroscopy (FTIR) has been used to characterize 
polyanhydrides by identification of a carboxylic anhydride doublet located between 1670 
and 1800 cm-1 9.  Aromatics normally show peaks at 1720 and 1780 cm-1, aliphatics at 
1740 and 1810 cm-1; degradation of the polymer can be monitored by the ratio of the 
14 
 
peaks of 1810 and 1700 cm-1.  Fourier transform Raman spectroscopy (FTRS) is used to 
determine how the monomer composition changes when copolymerized with another 
monomer by monitoring the methylene bands.  These bands can be altered due to 
deformation, stretching, rocking, and twisting.  The location of carbonyl bands, present in 
all polyanhydrides, can also be an indication of the monomer change.  Aromatic 
polyanhydrides show the carbonyl band pairs at 1764 and 1712 cm-1; for aliphatic 
polyanhydrides, the bands are displayed at 1804 and 1739 cm-1 27. 
 
1H-NMR is often used to determine the copolymer composition, the average length of the 
sequence, the frequency of copolymer sequences, and the chain structure, such as block, 
alternating, or random (given by degree of randomness) 28.  Protons in aromatic 
polyanhydrides, due to being closer to electronegative groups, exhibit chemical shifts at 
6.5 to 8.5 ppm; aliphatic protons exhibit higher chemical shifts of 1 to 2 ppm 29. 
 
For determining molecular weight, GPC is the most common method to use.  
Characteristic weight average molecular weight (Mw) of polyanhydrides vary from 5,000 
to 300,000; polydispersities range from 2 to 15, and typically rise with increasing Mw 28.  
Viscosity measurements can also be used for verifying molecular weight; the relationship 
between viscosity and molecular weight can be established using the Mark-Houwink 
equation.  For example, for Poly(CPP-SA), the relationship was found to be 
[ ] 658.0723 1088.3
3 w
C
CHCl M
−×=oη  
Here, η is the intrinsic viscosity 28. 
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Differential scanning calorimetry (DSC) can be used to verify thermal properties, such as 
melting and glass transition temperatures, as well as heats of fusion.  Typically, the glass 
transition temperature, Tg, decreases with increasing chain length of the polymer 30. For 
processing polyanhydrides into drug delivery devices, Tm is needed to dictate the lowest 
temperature needed for melt pressing or molding, while Tg determines the lowest 
temperature for compression molding 31.  A wider range of values between Tg and Tm is 
observed with Poly(CPH) (32°C and 140°C, respectively) 32 than with Poly(SA) (62° and 
79°C, respectively) 30; copolymers exhibit temperatures between the two homopolymers .  
 
Wide angle X-ray diffraction, a combination of differential scanning calorimetry (DSC) 
and X-ray diffraction, and 1H-NMR can be used to determine the crystallinity of 
polyanhydrides 33,34.  In general, most aromatic and aliphatic homopolymers were found 
to be semi-crystalline.  A copolymer rich in either monomer exhibited a slight decrease in 
crystallinity; while copolymerizing at equal mole ratios, the resulting polymers became 
amorphous 33. 
 
2.2.5 Degradation and erosion 
Polymer degradation can occur by either enzymatic or hydrolytic degradation; the latter is 
much preferred for drug delivery applications, because of large amount of water naturally 
present in the body 35.  Polyanhydrides degrade by the hydrolysis of their anhydride 
linkages, in the presence of water, to form dicarboxylic acids, and further more to form 
carbon dioxide and water.  While monomeric anhydrides degrade in the presence of both 
acids and bases, hydrolysis of polyanhydrides are base catalyzed 5.  To impede the 
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degradation rate, methylene groups can be introduced into the core of the polymer.  
Degradation can be affected by many factors, such as pH of the medium and 
hydrophobicity and crystallinity of the polymer.  As expected, the higher the 
hydrophobicity of the polymer, the slower the degradation rate, as the rate at which water 
penetrates into the bulk slows in correlation 35.  Polyanhydride degradation is base 
catalyzed; an increase in pH of the medium increases the rate of degradation; acidic 
media tends to impede and can even halt degradation in some cases 9.  An increase in 
crystallinity of a polyanhydride can also lead to a slower degradation rate 36. 
 
Two types of polymer erosion mechanisms exist: bulk erosion and surface erosion 35.  
Considering polyanhydrides are primarily hydrophobic, they are characterized as surface 
eroding, meaning they degrade layer by layer, and material is only lost from the surface.  
This is opposed to bulk erodible polymers, which degrade as a whole, since water 
penetrates into the bulk.  Figure 2.5 gives a schematic of bulk eroding versus surface 
eroding mechanisms.  
 
Figure 2.6 – Bulk eroding versus surface eroding mechanisms 
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Biodegradation is the process by which the polymers degrade into products that are either 
metabolites or could be easily metabolized by a living organism.  Degradation varies 
drastically depending on the monomer used.  Poly(sebacic acid) and Poly(1,6-bis-(p-
carboxyphenoxy)hexane, for example, degrade in 54 days and 1 year, respectively, in 
saline37.  By combining different ratios of polyanhydride monomers during the 
fabrication of copolymers, degradation rates can be tailored for a specific application. 
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Figure 2.7 – Hydrolysis reaction of polyanhydrides 
 
2.2.6 Polyanhydrides for drug delivery 
Polyanhydrides were not researched for drug delivery applications until 1983, when 
Langer and co-workers reported their potential for controlled drug delivery, based on 
their biodegradable properties 38.  There are several reasons why polyanhydrides are 
suitable candidates for use in drug delivery applications.  Due to their ability to surface 
erode, polyanhydrides exhibit a predictable release rate; this can be modified simply by 
changing the chemistry or the molecular weight.  As mentioned previously, 
polyanhydrides are quick and easy to produce, and can be manufactured in a variety of 
ways, depending on the properties of the preceding monomers.  Finally, polyanhydrides 
are non-toxic and non-mutagenic, and degrade into carboxylic acids that are further 
catabolized intocarbon dioxide and water.  For use in medical applications, they can be 
sterilized by terminal-γ-irradiation without affecting molecular weight or structure 39-41.   
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One of the most prominent uses of polyanhydrides is with the Gliadel® wafer, comprised 
a copolymer of 1,3-bis(p-carboxyphenoxy)propane and sebacic acid.  Approved by the 
Food and Drug Administration (FDA) in 1996, Gliadel® is used to deliver bis-
chloroethlylnitrosourea (BCNU) to treat a form of brain cancer known as glioblastoma 
multiforme 42.   
 
2.3 Microspheres 
Biodegradable polymers are preferred for parenteral drug delivery systems as there is no 
need to remove any device post implantation.  A size of less than 25 μm is normally 
preferred for such applications; this size also allows for delivery into the tissue by the use 
of a syringe 43. 
 
2.3.1 Fabrication 
The choice of which fabrication method to use in order to produce the appropriate 
microspheres depends on the properties of both the desired polymer and the drug to be 
encapsulated, including hydrophobicity, crystallinity, thermal properties, and stability.  
Four of the most common ways to fabricate microspheres include hot-melt 
microencapsulation, solvent evaporation, solvent removal, and spray drying.   
 
2.3.1.1 Hot-melt microencapsulation 
Hot-melt microencapsulation involves adding a mixture of melted polymer and solidified 
drug particles to a polymer immiscible-solvent at a temperature slightly above the 
melting point of the polymer.  The spherical structure forms when the solution is cooled; 
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the resulting microspheres are rinsed with a nonsolvent, such as petroleum ether.  
Adjusting the stirring speed can change the size of the uniform microspheres.  While the 
microspheres formed have a smooth surface, only thermolabile polymers can be 
fabricated by this process due to the high temperatures used 44. 
 
2.3.1.2 Solvent evaporation 
An oil-in-water emulsion is a simple method for making microspheres; since heat is not 
involved, this method can be used to produce microspheres from heat-sensitive polymers.  
The polymer is dissolved in an organic solvent, such as methylene chloride, and stirred 
into an aqueous solution of surfactant, such as poly(vinyl acetate).  The resulting solution 
is stirred for two hours, which is sufficient time to allow the organic solvent to evaporate 
completely, and leaves behind the hardened microspheres 45-49 
 
For hydrophilic polymers, a double-emulsion, consisting of water-oil-water, can be used. 
The aforementioned oil-in-water method is altered slightly by adding a small amount of 
the aqueous phase to the organic solution prior to dispersing 50.  However, the problem 
exists that the process is aqueous and increases the possibility that the polymer can begin 
to degrade during the fabrication of the microspheres 51-54. 
 
2.3.1.3 Solvent removal 
A variation of this technique is sometimes referred to as solvent removal, though it is a 
similar process.  This is also referred to as solid-oil-oil emulsion.  The advantage of this 
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technique is that it prevents hydrolysis of the polyanhydride by eliminating water from 
the process 50. 
 
Polymers and excipients are dissolved in an organic solvent, such as methylene chloride.  
An organic oil nonsolvent, such as silicon or paraffin oil, is slowly added to the solution 
with stirring; a surfactant such a Span 85 is slowly introduced.  The emulsion is added to 
an immiscible nonsolvent, such as petroleum ether or hexane, and stirred for a couple 
hours; during this time, the oil slowly extracts the organic solvent, and microspheres are 
formed 55,56. 
 
2.3.1.4 Spray drying 
Mathiowitz developed a spray-drying method for producing microspheres; the 
polyanhydrides and drugs were dissolved into methylene chloride and sprayed through a 
0.5 mm diameter atomizing nozzle.  The microspheres are dried by a flow of nitrogen gas 
as they descend to the base of the spray dryer.  Lower crystallinity polymers, such as 
aromatics and copolymers of aromatics and aliphatics, produced spherical, smooth 
microspheres.  Aliphatic polymers tended to have a rutted surface; despite this, the 
method is conducive as it is fast and results in the production of uniform microspheres, 1-
5 μm in diameter, and can easily be scaled up 31,57.  This method is preferred for making 
microspheres as it can be easily scaled up for industrial applications and also can be used 
for heat-sensitive drugs. 
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A modified spray drying technique, known as cryogenic atomization, was first described 
by Johnson and Cleland with polylactic-co-glycolic acid 58,59.  The polymer and any 
protein or other excipients are dissolved in a solvent such as methylene chloride, acetone, 
or ethyl acetate, and sprayed over frozen ethanol topped with liquid nitrogen.  The liquid 
nitrogen acts to hold the microsphere structure intact by freezing and gradually evaporate; 
the ethanol removes the residual solvents.  The solution is filtered, and microspheres 
were found to be between 50 and 60 µm.   
 
2.3.2 Characterization 
Due to the small physical size of microspheres, microscopy is generally used to 
determine the relative size and shape of the microsphere.  Light microscopy is a simple 
method for imaging, as it requires no special sample preparation.  For much higher 
resolution, scanning electron microscopy (SEM) can be used; however, since polymers 
are nonconducting materials, they are coated with a thin layer of gold to allow for 
imaging 60.  SEM can also be used to view cross sections of cut microspheres, due to the 
ability to tilt the sample holder upon imaging 61; this ensures the microsphere is a solid 
object. 
  
For drug-loaded microspheres, confocal fluorescence microscopy is a useful method for 
detecting the distribution of the drug within the microspheres.  By staining the drug with 
a dye, such as carboxyfluorescein or Nile red, and imaging at different wavelengths (550 
nm or 600 nm, respectively), the surface of the microspheres can be analyzed for 
dispersal of the drug 60,61. 
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2.3.3  Release 
Due to the surface erosion characteristics of polyanhydrides, microspheres of these 
polymers have predictable, zero-order release kinetics.  Polyanhydride microspheres have 
been shown to provide a sustained release of BSA-FITC, and with a differing ratio of 
copolymers, can offer a differing release profile 62.  Manipulation of the ratio of 
monomers used in copolymers is the simplest way to alter the release kinetics 63.  Other 
factors not as easily controlled can change the way the polyanhydrides release the drug.  
Since polyanhydrides are base-catalyzed, a higher pH of the surrounding medium can 
lead to a faster release rate of drug.  A microsphere with a more porous surface has been 
shown to degrade faster than non-porous surfaces.  Size and shape of the microsphere can 
also alter the release kinetics; in general, smaller microspheres have faster release 
kinetics due to an increased surface area to volume ratio.  However, drug solubility in 
water and fabrication method can affect this trend 64. Drug hydrophobicity also can play a 
role in release kinetics; the higher the hydrophobicity, the slower the release rate. 
 
When a drug is incorporated into a microsphere, some of the particles are adsorbed onto 
the polymer’s surface rather than fully incorporated into the microsphere.  Therefore, 
when immersed into a solution, the adsorbed drug immediately dissolves into solution, 
resulting in a large, instantaneous release of the drug; this is known as the burst effect.  
This phenomenon typically occurs upon incorporation of a hydrophilic drug.  An increase 
in drug size results in a larger burst 65.  
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2.4 Mechanisms of Immune Response 
2.4.1 Innate and adaptive immunity 
An immune response can be categorized as one of two types: innate or adaptive.  An 
innate immune response is non-specific, meaning it reacts to a pathogen, regardless of 
type, in a standard way.  It is active and functional at an early age, and will not change 
nor develop as one ages.  In contrast, an adaptive immune response is quite specific, and 
will develop only after an initial innate response occurs.  It will develop over the course 
of an individual’s life.  Memory cells develop as part of the adaptive immune response; 
therefore, upon re-exposure to prior infectious agent, the adaptive immune response will 
rapidly recall pathogen-specific effector mechanisms, thereby inducing a stronger 
reaction than the initial primary immune response.  Adaptive immunity occurs over the 
course of an individual’s life, and becomes stronger upon each subsequent encounter of 
the antigen 66. 
 
2.4.2 Major histocompatibility complex 
The major histocompatibility complex (MHC) is comprised of the molecules responsible 
for the recognition of foreign antigens.  There are two main types of MHC molecules, 
class I and class II; their differences lie not only in their structure, but also on the source 
of the antigen and the type of cells they provoke.   
 
All nucleated cells express class I MHC proteins; this presentation is known as the 
cellular response, and allows for recognition of non-self.  When nucleated cells become 
infected with a virus or bacteria, the protein of the pathogen is transferred to the cytosol.  
24 
 
Both the pathogen’s protein and self proteins are degraded by the proteasome, and the 
fragments are transferred to the cell’s endoplasmic reticulum.  There, the fragments bind 
to the peptide binding clefts of the class I MHC complex, and are translocated to the 
plasma membrane where they can now react with the specific T cell receptor..  Since 
viral proteins are made in the cells cytoplasm, MHC I present these foreign peptides to 
CD8+ cytootoxic T cells.  Once activated, these cells, form synapses between their TCR 
and the peptide MHC I complex and subsequently release the cytotoxins perforin and 
granzymes.  Perforins form pores within the target cell’s plasma, which allows 
granzymes to migrate into the plasma membrane, resulting in cell death 66. 
 
In addition to MHC I, antigen presenting cells, such as dendritic cells or macrophages, 
also express class II MHC proteins.  Induction of an immune response by this process is 
referred to as humoral or antibody response.  This process starts with the pathogen being 
engulfed by the antigen presenting cell; following proteolytic cleavage, the peptides are 
retained within the endosome.  At this point, the peptides are bound by the class II MHC 
molecule that is then translocated to the cell surface. It presents the foreign antigens to 
the CD4+ cells.  Cytokines released from these activated CD4 helper T cells then either 
activate B cells,  phagocytes, or other T cells such as CD8+ T cells 66. 
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Figure 2.7 – Major Histocompatibility Complex and Mechanisms of Immune Response 
 
2.4.3 Dendritic cells 
The term “dendritic cell” was first documented in 1973, by Steinman and Cohn 67, and 
are termed because of their branches, or “dendrites” that extend from the cell body’s 
exterior.  Found in the lymph, spleen, skin, and bloodstream, they are a type of antigen 
presenting cell, meaning they display the foreign antigen on the surface.  Immature 
dendritic cells (DCs) constantly sample the surroundings for pathogens such as viruses 
and bacteria. Once they have come into contact with such pathogens, they engulf it 
through phagocytosis, migrate to the lymph nodes, and become mature.  Upon 
maturation, dendritic cells present the protein fragments, which are bound to class II 
MHC molecules, on their surface; this leads to a surge of class II molecule production.  
As antigen presenting cells, dendritic cells assign directives to both T and B cells.  
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Consequent to antigen presentation, CD4+ T cells recognize this peptide complex, and 
either activate B cells to differentiate into antibody secreting plasma cells or stimulate 
other T cells, such as CD8+ cytotoxic T cells 66,68-71. 
 
Unfortunately, naïve T cells are not activated by MHC molecules alone; they also need a 
co-stimulatory signal expressed by an antigen presenting cell 66.   Co-stimulatory 
molecules are upregulated on antigen presenting cells following stimulation with a 
pathogen or pathogen mimicking molecules, and are not specific towards a certain 
antigen.  Co-stimulatory molecules commonly contributing to T cell activation include 
CD80, CD86, and CD40, which bind to CD28 and the C40 ligand on T cells, 
respectively.  The binding of CD40 to the CD40 ligand is not only important for 
activation of the T cell, but is also a necessary signal for T cell proliferation 66,70,71.  
Another important molecule recognized by DCs is the intercellular adhesion molecule 
(ICAM).  ICAM-3, in particular, is found on the surface of naïve T-cells, and has a strong 
attraction for the DC specific mannose C-type lectin of DC-SIGN (dendritic cell specific 
ICAM-3 grabbing non-integrin), also known as CD209 66,72.  Found in high levels among 
mature dendritic cells, DC-SIGN is hypothesized to be responsible for recruiting and 
trafficking resting T cells through binding of ICAM-2 and promoting T cell proliferation 
72,73. 
 
Dendritic cells, when activated, also secrete cytokines, which are proteins that affect the 
vigor and/or bias of the immune response.  As a consequence of IL-12 secretion from 
DCs, T cells are induced to become TH1 cells.  These CD4+ T cells typically produce 
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IFN-γ, the cytokine responsible for initially activating macrophages, and TNF-β, which, 
in addition to activating macrophages, hinders B ells and can prove toxic to some cells.  
The release of IL-10 from DCs will induce CD4+ T cells to become TH2 cells that secrete 
IL-4, IL-5, IL-6, IL-13, as well as IL-10.  The TH2 cytokines are critical for the 
differentiation of B cells to inhibit the activation of macrophages, and attenuate 
inflammation.  In the absence of DC activation (i.e., no co-stimulatory signals), a TH0 
response is induced, that is, typically characterized by the secretion of IL-2, as well as IL-
4 and low amounts of IFN-γ 66. 
 
2.5 Adjuvants and Vaccines 
Derived from the Latin word ‘adjuvare’ meaning ‘to help’, adjuvants are compounds 
used conjunction with antigens to boost the body’s immunological response 74.  In 1926, 
aluminum-based compounds (aluminum hydroxide or phosphate, primarily) were shown 
to enhance the effects of immunizing diphtheria toxoid, and these compounds are still the 
primary adjuvants used today and the only ones approved for use in humans by the Food 
and Drug Administration in the United States 75,76.  However, these adjuvants are rather 
poor at inducing cellular immune responses.  Other adjuvants have been investigated, 
such as Freund’s complete adjuvant and the inclusion of lipopolysaccharides (LPS); 
however, because of their toxicity, they have been deemed unfit for use in humans 77,78.  
A need still remains to find adjuvants with minimal toxicity that is cheap to manufacture, 
and has no side effects.   
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2.5.1 Novel therapies using polymers 
According to the World Health Organization, an estimated 27 million infants are lacking 
proper immunizations, thus causing them to be more vulnerable to easily avoided 
diseases 79.  Many immunizations require more than one dose to provide effective 
immunity; one such example is the vaccine against chicken pox, proven to not be 
protective when only one dose is given 80.  Additionally, in less developed countries, it 
may be difficult for patients to receive more than one dose of a vaccine, due to locations 
of clinics or ability to reach one 81.  One feasible approach would be to produce a vaccine 
that, with one dose, could give controlled release over a pre-determined period of time 82; 
a schematic of this is shown in Figure 2.8.   
 
The first controlled release of an antigen from a polymer, poly(ethylene-co-vinyl acetate) 
(EVA), was demonstrated in the late 1970s 83,84; however, EVA is not a biodegradable 
polymer, meaning it needs to be removed after the antigen has fully released.  
Biodegradable systems, involving polymers such as poly(lactic-co-glycolic acid) (PLGA) 
and polyanhydrides, have been proven as an effective alternative to alum-based adjuvants 
85 and are able to provide a continual and controlled release over a given period of time.  
In addition, microsphere formulations are preferred, as there is no surgery required for 
implantation; a size of 25 μm in diameter is preferential for delivery through a syringe43.  
Ideally, microspheres should be less than 10 μm, which can lead to efficient phagocytosis 
by dendritic cells, and thus effective antigen presentation to immune cells 86.   
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Figure 2.8 – Conventional release versus controlled release 
 
A single injection of microspheres comprised of PLGA have been used successfully to 
deliver antigens such as tetanus toxoid 87, diphtheria toxoid 88, influenza virus 89 to induce 
an equivalent antibody response to that observed following repeated doses of 
conventional vaccines. The most prominent example of PLGA biodegradable 
microspheres approved by the FDA, in 1989, and currently on the market, is the Lupron 
Depot®.  It provides palliative treatment for prostate cancer through release of leuprolide 
acetate from the microspheres 90.   
 
Because, PLGA is a bulk-eroding polymer; this can potentially lead to bulk water 
penetration, which can initiate water-induced covalent aggregation of the encapsulated 
antigen or drug.  Another problem that can affect the stability of the encapsulated 
compound is the low pH generated following the degradation of PLGA into lactic and 
glycolic acid 91, as well as inside the PLGA drug delivery device because of the ability of 
water to penetrate the bulk eroding device 92.  Such extreme pHs can lead to protein 
unfolding, leading to denaturation and possibly irreversible aggregation 93.  
Polyanhydrides are thus superior to PLGA in these circumstances; in addition to a higher 
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degradation pH 94, the surface-eroding polyanhydrides prevent water penetration into the 
bulk.  Polyanhydrides have the advantage of tailored release kinetics, since by simply 
changing the chemistry of the monomer can ultimately change the rate of antigen release.  
This is favored in vaccine situations, as it allows the number of immunizations to 
decrease while providing tailored release kinetics for any application.  While the only 
application of polyanhydrides thus far is the Gliadel® wafer 42, polyanhydrides for 
vaccine applications appear to be very promising. A study with polyanhydride 
microspheres demonstrated therelease of tetanus toxoid in vivo with a single injection.  In 
addition, important immunomodulatory properties of polyanhydride delivery vehicles 
were noted; by changing the chemistry of the copolymers, a balanced immune response 
could be obtained 85.  The ability to modulate the immune response makes the 
polyanhydride delivery vehicle versatile, especially when compared to traditional alum-
based vaccines, which have only been demonstrated to provide a TH2 (humoral) response 
95. 
 
2.6 Conclusions 
Biodegradable polymers have been used as carriers for the controlled delivery of drugs 
and proteins for over two decades. Polyanhydrides, in particular, show tremendous 
promise for use as drug delivery vehicles.  A variety of synthesis techniques allows for 
monomers of various structures and thermal properties to be polymerized into 
polyanhydrides.  Formulating the surface-eroding polyanhydrides into microspheres is 
the simplest way to deliver a drug; by altering the chemistry of the backbone or 
copolymerizing with other monomers, polyanhydride microspheres can exhibit a wide 
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range of predictable and controlled release kinetics.  Since polyanhydrides degrade into 
dicarboxylic acids, there is no need to removed post-implantation, unlike other 
biomaterials.  In order for polyanhydrides to be deemed a viable candidate for 
replacement of traditional vaccines, studies need to be conducted to ensure protein 
stability and an adequate immune response, two important factors in designing delivery 
devices. 
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CHAPTER 3 
RESEARCH OBJECTIVES AND ORGANIZATION 
3.1 Research Objectives 
As demonstrated in the previous chapters, polyanhydrides microspheres have shown 
great promise for development as vaccine delivery vehicles.  The overall goal of this 
work was to study the effect of polyanhydride chemistry on protein release kinetics, 
protein stability, and immune activation, leading to rational design of carriers for specific 
applications.  This study focuses on polyanhydrides based on the anhydride monomers of 
sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)3,6-dioxaoctane (CPTEG).  The two specific goals of this thesis 
research project were: 
 
Specific goal 1:  Determine how polymer chemistry and fabrication methods affect the 
release kinetics of proteins from polyanhydride microspheres and the stability of the 
released protein. 
 
Specific goal 2:  Investigate the surface marker expression of murine bone marrow-
derived dendritic cells by polyanhydride microspheres and prove that different 
chemistries can lead to distinct activation pathways of these immune cells. 
 
3.2 Thesis Organization 
Specific goal 1, discussed in Chapter 4, will focus on the controlled released of 
ovalbumin, a model antigen, from polyanhydride microspheres. This study will compare 
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two non-aqueous microsphere fabrication methods.  In addition, the chapter will present 
information on which polyanhydride chemistries preserve the primary structure and 
epitope availability of ovalbumin. 
 
Specific goal 2, discussed in Chapter 5, will address the effect of polyanhydride 
chemistry on the activation of dendritic cells.  The degree to which stimulation occurs is 
chemistry dependent, and varies for each surface marker investigated. 
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CHAPTER 4 
EFFECT OF POLYMER CHEMISTRY AND FABRICATION METHOD ON 
PROTEIN RELEASE AND STABILITY FROM  
POLYANHYDRIDE MICROSPHERES 
 
A paper to be submitted to Journal of Biomedical Materials Research, Part B 
 
Senja K. Lopac1,2, Maria P. Torres1, Jennifer H. Wilson-Welder3,  
Michael Wannemuehler3, Balaji Narasimhan1,4
 
4.1 Abstract 
The release kinetics and protein stability of ovalbumin-loaded polyanhydrides 
microspheres with varying chemistries were studied.  Polymers based on the anhydride 
monomers sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were chosen.  Microspheres were fabricated 
using two non-aqueous methods: a solid/oil/oil emulsion technique and cryogenic 
atomization.  Studies found no significant difference in release kinetics of ovalbumin.  
Ovalbumin released from microspheres prepared by cryogenic atomization was studied 
for preservation of primary structure by SDS-PAGE and availability of immunogenic 
epitopes by western blot.  The more hydrophilic polyanhydrides containing CPTEG 
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2 Primary researcher and author 
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showed more favorable protein stability, preserving both the immunological epitopes and 
the primary structure. 
 
4.2 Introduction 
Biodegradable polymers have been used as carriers for the controlled delivery of drugs 
and proteins for over two decades. These carriers have the advantages of providing 
sustained release over long periods of time, well-controlled release profiles, and 
biocompatibility. The most common biodegradable polymers used in drug delivery 
applications are polyesters such as poly(D,L-lactide-co-glycolide) (PLGA), 
polyanhydrides, and poly(ortho esters).  A potential draw-back in using the bulk-erodible 
PLGA for protein delivery is that the water penetration into the bulk is fast and that the 
degradation products are fairly acidic; for example, a pH of less than 3 for degradation 
products 1 and a pH of 2 inside a PLGA drug delivery device 2 have been reported.  
Studies have shown that at these pH values, some proteins can undergo denaturation by 
unfolding, and in some cases, irreversible aggregation 3.  This is problematic for most 
proteins because a loss in structure is detrimental to function. In comparison, the pH 
values produced by polyanhydride degradation products are much higher, notably 4.2 for 
sebacic acid (SA) and 5.5 for 1,6-bis(p-carboxyphenoxy)hexane (CPH) 4.  The 
hydrophobic chemistry of polyanhydrides helps prevent water-induced covalent 
aggregation of proteins since water penetration into the bulk is negligible; however, non-
covalent aggregation due to hydrophobic interactions may result 5,6.  This has motivated 
research to make these materials less hydrophobic 7,8.  This was achieved by 
incorporating oligomeric ethylene glycol units, such as triethylene glycol, into the 
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backbone of hydrophobic aromatic polyanhydrides, such as Poly(CPH), leading to 
amphiphilic polymers with mixed erosion mechanisms and both covalent and non-
covalent aggregation of proteins can be reduced 7.   
 
Polyanhydrides were not studied for drug delivery applications until 1983, when Langer 
and co-workers reported their potential for controlled drug delivery, based on their 
biodegradable properties, and non-toxic and non-mutagenic nature 9.  Due to their ability 
to surface erode, polyanhydrides exhibit a predictable zero-order release rate, making 
them attractive candidates for drug delivery applications 10.  Degradation of 
polyanhydrides occurs by base-catalyzed hydrolysis of their anhydride linkages, in the 
presence of water, to form dicarboxylic acids; their rate of degradation depends upon on 
the monomers used 11-13.  Poly(sebacic acid) (SA) and Poly(1,6-bis-(p-
carboxyphenoxy)hexane (CPH) tablets, for example, degrade in 54 days and 1 year, 
respectively 14.  In contrast, the ethylene glycol containing polyanhydride, Poly(1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane) (Poly(CPTEG)) degrades by 80% in 28 days 7.  Thus, 
by combining different anhydride monomers in various ratios, copolymer degradation 
rates can be tailored for specific applications 15. 
 
Biodegradable polymers are also preferred for parenteral drug delivery systems as there is 
no need to remove them following implantation.  A size of less than 25 μm is normally 
preferred for such applications; this size also allows for delivery into the tissue by the use 
of a syringe and needle 16.  Typical methods for microsphere fabrication include hot melt 
microencapsulation 17, double emulsion 10,18-22,  spray drying 23-24, and cryogenic 
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atomization 20,25-28. In particular, previous research has shown that double emulsion 
methods in which water/organic interfaces are present are potentially detrimental for 
protein stabilization 21,29-32.  Thus, several groups have focused on developing non-
aqueous methods for preparing protein-loaded microspheres. Two commonly used non-
aqueous techniques for fabricating microspheres include solid-oil-oil (S/O/O) double 
emulsion and cryogenic atomization (CA); these techniques prevent hydrolysis of the 
polymer by eliminating water from the process 33. 
 
The objective of this work is to define the effects of polymer chemistry and fabrication 
methods on the release kinetics of proteins from polyanhydride microspheres and the 
stability of the subsequent released protein.  Polymer chemistries based on the anhydride 
monomers SA, CPH, and CPTEG were chosen (Fig. 4.1).  Ovalbumin (ova) from chicken 
egg white was selected as the model protein.  Microspheres were fabricated by solid-oil-
oil and cryogenic atomization techniques. 
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Figure 4.8 – Chemical structures of polymers used, from top, left to right: poly (sebacic 
acid), poly (1,6-bis(p-carboxyphenoxy)hexane), and poly (1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane), where n represents the number of repeating monomer units. 
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4.3 Materials and Methods 
4.3.1 Materials 
Albumin from chicken egg whites (ovalbumin), 1,6-dibromohexane, 4-hydroxybenzoic 
acid, 1-methyl-2-pyrrolidinone, sebacic acid (99%), monoclonal anti-chicken egg 
albumin (clone Ova-14), rabbit anti-chicken egg albumin, alkaline phosphatase 
conjugated goat anti-rabbit IgG, and tri-ethylene glycol were purchased from Sigma-
Aldrich (St. Louis, MO).  4-p-fluorobenzonitrile was purchased from Apollo Scientific 
(Cheshire, UK).  Acetic acid, acetic anhydride, acetone, acetonitrile, dimethyl 
formamide, ethyl ether, heptane, hexane, methylene chloride, petroleum ether, potassium 
carbonate, sodium hydroxide, sulfuric acid, and toluene were purchased from Fisher 
Scientific (Fairlaw, NJ).  Dialysis cassettes, bicinchoninic acid (BCA) assay reagents, and 
GelCode blue were purchased from Pierce (Rockford, IL). Low protein molecular weight 
standards were purchased from BioRad (Hercules, CA).  12% tris-glycine PAGEr 
Duramide Precast Gels were purchased from Lonza Bioscience (Basel, Switzerland).  
Dow Corning oil, ethanol, and liquid nitrogen were obtained from in-house bulk chemical 
supplies. 
 
4.3.2 Monomer/polymer synthesis 
To produce the CPH monomer, the method described by Conix 34 for synthesizing 1,3-
bis(p-carboxyphenoxy)propane was altered, using 1,6-dibromohexane instead of 1,3-
dibromopropane.  Prepolymers for both CPH and SA were synthesized using a method 
outlined by Shen 35; copolymers of these compositions and Poly(SA) were synthesized by 
melt condensation using a procedure outlined by Kipper and coworkers 36.  The CPTEG 
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monomer and polymers of CPTEG and CPH were produced using a technique described 
by Torres et al 7.  Polymers, pre-polymers, and diacids were characterized by 1H NMR, 
using a Varian VXR-300 NMR (Palo Alto, CA), to ensure purity; a Waters GPC 
(Milford, MA) was also used to measure the polymer molecular weight. 
 
4.3.3 Protein 
Ova from chicken egg whites was lyophilized prior to use.  Lyophilization occurred by 
pumping ova (50 mg) in 50 mM ammonia bicarbonate solution (10 mL) over 400 mL of 
liquid nitrogen.  The liquid nitrogen was allowed to boil off, and the remaining protein 
was placed in a dryer oven overnight; denaturation of freeze-thawed ova at a neutral pH 
is highly unlikely 37. 
 
4.3.4 Contact angle measurements 
To characterize the relative hydrophobicity of the polymers, contact angle measurements 
were carried out.  Polymers were dissolved in a 2.5 w/v% solution of tetrahydrofuran (for 
Poly(CPTEG) and CPTEG-containing copolymers), or methylene chloride (for 
Poly(CPH), Poly(SA), and their copolymers). After filtering solutions with 0.2 µm filters, 
the solutions were pipetted onto separate round glass cover slides. After the solvent dried, 
more solution was added until a suitable polymer thickness was obtained. To measure the 
contact angle, a water droplet was carefully placed on the surface of the polymer film 
immediately prior to imaging with a CCD camera. Image J software (NIH, Bethesda, 
MD) was used to measure the contact angle. The experiment was performed in triplicate. 
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4.3.5 Microsphere fabrication methods 
Two non-aqueous methods were used to fabricate polyanhydride microspheres: solid-oil-
oil emulsion and cryogenic atomization.  Previous research has demonstrated that these 
methods are effective at encapsulating and stabilizing proteins 4,20. 
 
4.3.5.1 Solid-oil-oil emulsion 
This method was modified from a previously published procedure 21.  100 mg of polymer 
and 6 mg of ova were dissolved in methylene chloride.  A Tissue-TearorTM homogenizer 
(Biospec Products Inc., Bartlesville, OK) was used agitate the solution for one minute.  
For the second emulsion, Dow Corning oil and methylene chloride were added while the 
homogenizer was turned down to 10000 rpm, to allow for thorough mixing during 
addition.  Again, the homogenizer was used for one minute.  The various parameters used 
for each emulsion step for the different polymer chemistries are shown in Table 4.1.  The 
solution was added drop wise to a beaker of 200 mL of heptane immersed in an ice bath 
and stirred for two hours using a Caframo overhead stirrer (Wiarton, Ontario, Canada) set 
at 300 rpm.  Finally, the microspheres were filtered and placed in a vacuum oven 
overnight to eliminate any residual heptane. 
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Table 4.1 – Parameters for solid/oil/oil double emulsion  
 Methylene 
chloride for 
inner emulsion 
Rate for inner 
emulsion 
homogenization 
Rate for outer emulsion 
homogenization 
20:80 CPTEG:CPH 2 mL 20,000 rpm 3 min 
3 mL oil/4 mL MeCl2
20,000 rpm, 3 min 
Poly(CPTEG) and 
50:50 CPTEG:CPH 2 mL 
20,000 rpm 
3 min 
4 mL oil/6 mL MeCl2
20,000 rpm, 3 min 
Poly(SA) 3 mL 30,000 rpm 1 min 
3 mL oil/4 mL MeCl2
20000 rpm, 1 min 
20:80 CPH:SA 2 mL 30000 rpm 1 min 
3 mL oil/4 mL MeCl2
30000 rpm, 1 min 
50:50 CPH:SA 2 mL 20000 rpm 1 min 
3 mL oil/4 mL MeCl2
30000 rpm, 1 min 
 
4.3.5.2 Cryogenic atomization 
Cryogenic atomization, which employs an ultrasonic generator to produce a fine mist, 
was also modified from previously published work 21.  100 mg of each polymer was 
dissolved in methylene chloride as shown in Table 4.2, with 6 mg of ova.  Using a glass 
syringe, 20 gauge capillary tube, and. programmable syringe pump (KD Scientific, 
Holliston, MA), the polymer solution was pumped over 200 mL of 200 proof ethanol 
(frozen by liquid nitrogen), leaving a small layer of liquid nitrogen overlaying the 
ethanol.  The atomizing mist was provided by an ultrasonic atomizing nozzle (SonoTek 
Corporation, Milton, NY).  The beakers were placed in a -80 °C freezer for three days to 
allow the liquid nitrogen to boil off, the ethanol to thaw, and the methylene chloride to 
slowly be extracted.  Afterwards, the microspheres were filtered and placed in a vacuum 
oven to dry overnight. 
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Table 4.2 – Parameters for cryogenic atomization  
 Methylene 
chloride Flow rate Wattage 
20:80 CPTEG:CPH, 
50:50 CPTEG:CPH, 
and Poly(CPTEG) 
7 mL 3 mL/min 1.5 W 
50:50 CPH:SA 3 mL 1.5 mL/min 2.5 W 
Poly(SA) and 
20:80 CPH:SA 3 mL 3 mL/min 1.5 W 
 
4.3.6 Microsphere characterization 
A JEOL 840A scanning electron microscope (SEM) was used to determine relative size 
and shape of microspheres.  Microspheres were smeared onto carbon stubs, coated with 
200Å of gold, and imaged. Size distribution was performed using Image J software (NIH, 
Bethesda, MD). 
  
Figure 4.2 – 50:50 CPH:SA microspheres fabricated by S/O/O (left) and CA methods.  
Scale bars represent 50 μm. 
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Figure 4.3 – 20:80 CPTEG:CPH microspheres fabricated by S/O/O (left) and CA 
methods.  Scale bars represent 20 μm. 
 
4.3.7 Ova release  
Microspheres (10 mg) of each chemistry and fabrication method were suspended in 1mL 
of phosphate buffer solution (pH 7.4) with 0.01% sodium azide and placed in an 
incubator at 37 °C and 100 rpm.  Release samples were collected two hours after the 
initial time point, daily for one week, and finally every other day for 30 days.  An aliquot 
of 750 µL was sampled each time and subsequently replaced with 750 µL of fresh 
phosphate buffer solution; samples were also centrifuged before sampling to ensure no 
microspheres were removed from the system.  In order to assay for the amount of protein 
release, a bicinchoninic acid (BCA) assay was run on each sample, in duplicate, as 
described by the manufacturer (Pierce). 
 
After one month of release, the samples were added to 10 kDa molecular weight cut-off 
dialysis cassettes to determine the amount of protein remaining inside the microspheres.  
The left over microspheres were suspended in 3 mL of 17 mM NaOH and sonicated to 
break up any microsphere aggregates.  The exposure to a high pH allows for fast 
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degradation of the polymer, since polyanhydride degradation is base-catalyzed 23.  Each 
release sample was added to dialysis cassettes and incubated for one week at 40 °C and 
100 rpm.  A BCA assay was run on each sample in triplicate.  The total protein loaded 
into the microspheres was calculated by adding the protein that was released in one 
month to the protein extracted from the remaining microspheres. The release data is 
presented as a cumulative fraction of protein released, which is normalized by the total 
protein loaded into the microspheres. 
 
4.3.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Ova-loaded microspheres (5%) were synthesized using cryogenic atomization.  15 mg of 
these microspheres were added to 1 mL of .phosphate buffer solution (pH 7.4), with 
0.01% sodium azide, and placed in an incubator at 37 °C and stirred at 100 rpm for 2 
hours; 750 μL of solution was removed and replaced with 2.75 mL of 0.01 mM NaOH 
solution.  This was performed to rid the solution of absorbed protein and to ensure that all 
analysis was performed on released protein.  The microspheres were added to 10 kDa 
molecular weight cut-off dialysis cassettes, placed in 1 L of 0.01 mM NaOH solution, 
and incubated for 2 weeks at 40 °C and 100 rpm.  After two weeks, the solution was 
removed from the dialysis cassette and centrifuged for 10 minutes at 10,000 rpm to 
isolate the polymer remaining in the solution.  A BCA assay, performed in triplicate, was 
used to determine the concentration of ova released from the microspheres. 
 
Using the concentration from the BCA assay, 2 μg of protein from each sample was 
placed on a rotovap until completely dry. Samples were prepared under reducing 
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conditions by adding 20 μL of 2-mercaptoethanol sample buffer to each sample and 
placing samples on a heating block at 90 °C for 10 minutes to break up the disulfide 
linkages.  The gels were made in triplicate, to allow for two to be used for western blot 
analysis (described below).  Gels were run at a constant voltage of 120 V until the dye 
front reached the bottom.  The gel set aside for SDS-PAGE analysis was rinsed with DI 
water and placed in gel fixative (50% methanol, 36% DI water, 14% acetic acid) 
overnight.  The next day, the gel was stained with Gelcode blue for a few hours and 
destained with water overnight; the staining process was repeated to obtain a darker 
stained gel.  The gel was placed between cellophane sheets and dried in a jet drier for 2 
hours. 
 
4.3.9 Western blot 
For the polyclonal western blot analysis, the gels were immediately removed after gel 
electrophoresis, placed between filter paper and a PVDF membrane, and placed back in 
the electrophoresis chamber for 3 hours at a constant current of 70 mA.  The membranes 
were blocked with a casein solution of TBST (tris buffer solution with 0.05% Tween, pH 
7.6) and milk powder overnight.  The following day, the membranes were rinsed in DI 
water, placed in a 50 mL centrifuge tube, and 12 μL of primary antibody (anti-Ova 
developed in rabbit) in TBST (1:1000) was added.   The membranes were spun for four 
hours, washed thrice with TBST to remove any unbound antibody, and placed back on 
the spinner with 12 μL of secondary antibody (anti-rabbit IgG alkaline phosphate 
developed in goat) in TBST (1:1000).  After two hours, the membranes were removed 
and rinsed thrice with TBST.  A colorimetric detection method with napthol phosphate 
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and fast red solution was used to reveal bands.  The membranes were air-dried between 
paper towels. 
 
4.4 Results 
4.4.1 Contact angle 
In order to assess the hydrophobicities of the various polymers, the contact angles of each 
of the polymers were measured, as shown in Figure 4.4.  As expected, Poly(CPTEG), the 
most hydrophilic and bulk-erodible polymer with a fast degradation profile (within 
weeks7), has a contact angle of 29°, the smallest among all the polymer chemistries 
tested.  In contrast, Poly(CPH), which is the most hydrophobic and surface-erodible 
polymer, and takes years to degrade38 has the highest contact angle of 60°.  As Figure 4.5 
demonstrates, an increase in CPH content within the CPTEG:CPH copolymers results in 
an increase in contact angle, which is consistent with an increase in hydrophobicity.  In 
the surface erodible CPH:SA system, since both CPH and SA homopolymers are 
hydrophobic, their copolymers have relatively similar hydrophobicities, as evidenced by 
contact angles that are statistically indistinguishable from each other.   
 
Figure 4.4 – Optical microscope images of Poly(CPH) (left) and Poly(CPTEG) (right) 
used for contact angle measurements 
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Figure 4.5 – Contact angle of all polyanhydride compositions. Error bars indicate 
standard deviations. 
 
4.4.2 Release of ovalbumin from polyanhydride microspheres 
SEM images of 50:50 CPH:SA and 20:80 CPTEG:CPH fabricated by S/O/O and CA 
methods are shown in Figures 4.2 and 4.3.  Size distributions of the CPTEG particles 
ranged from 4 to 60 μm for S/O/O, with the majority being between 10 and 15 μm in 
diameter, and 2 to 16 μm in diameter for CA microspheres 20.  For CPH:SA, the majority 
of the microspheres fell in the 6 to 10 μm diameter range for both fabrication methods. 
 
Figures 4.6 and 4.7 demonstrate the release profiles of ova from Poly(SA), 20:80 
CPH:SA and 50:50 CPH:SA copolymer microspheres fabricated by solid-oil-oil and 
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cryogenic atomization fabrication methods.  As shown, all these chemistries exhibit near 
zero-order release kinetics after the initial burst of protein, which is consistent with 
previous work 21.  Each polyanhydride chemistry exhibited a different release rate, but 
upon comparing the two methods, this was found to be unrelated to the fabrication 
method.  However, protein was released from Poly(SA) microspheres for a longer time 
(30 days) for solid-oil-oil fabrication than cryogenic atomization (6 days); however, both 
systems released 90% of the encapsulated protein at the end of the thirty day time period.  
In the CPH:SA system, as the polymer hydrophobicity increased, the release rate of the 
protein decreased. 
 
In addition, the choice of method also influences the size of the burst.  Microspheres 
produced by the S/O/O technique experienced a smaller initial burst of protein.  This 
could be attributed to the interplay between two phenomena: the rate at which the 
polymer precipitated during microsphere formation, and the rate at which the methylene 
chloride was extracted into the non-solvent to form the microspheres.  Also, 
hydrophobicity seemed to have an influence, as a greater difference in initial bursts was 
noted for the more hydrophilic Poly(SA) than the copolymers. 
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Figures 4.6 and 4.7 – Release of ova from Poly(SA) and CPH:SA copolymer 
microspheres using solid/oil/oil double emulsion (left) and cryogenic atomization (right) 
fabrication techniques. Error bars indicate standard deviations. 
 
Figures 4.8 and 4.9 demonstrates the ova release profiles from Poly(CPTEG), 20:80 
CPTEG:CPH and 50:50 CPTEG:CPH copolymer microspheres fabricated by S/O/O and 
CA methods.  Since Poly(CPTEG) is bulk-eroding, the protein release kinetics are not 
directly proportional to the degradation kinetics, but rather depend upon a combination of 
degradation, water swelling, and diffusion 7.  While one would expect the Poly(CPTEG) 
to have the fastest release profile, the 50:50 CPTEG:CPH copolymer actually releases 
protein at the same rate (for S/O/O) or slightly faster (for CA) than the Poly(CPTEG) 
homopolymer.  Previous work has shown that even though the mass loss (i.e., erosion) 
was consistent with the hydrophobicities of Poly(CPTEG) and 50:50 CPTEG:CPH 
copolymer, the water swelling and polymer degradation rates of both chemistries were 
very similar7.  Our data is consistent with these observations (Figures 4.8 and 4.9).  On 
the other hand, the 20:80 CPTEG:CPH microspheres released ova at a slower rate, and 
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both fabrication methods correlated in their sustained release profiles by releasing ~50% 
of protein in 1 month.  
 
Again, the only variation of release kinetics as a result of the fabrication methods is in the 
initial burst; Poly(CPTEG) microspheres demonstrated the largest difference in burst (8% 
in S/O/O vs. 42% in CA).  This is consistent with the observations reported for the 
CPH:SA system, considering Poly(CPTEG) is the most hydrophilic polyanhydride tested. 
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Figures 4.8 and 4.9 – Release of ova from Poly(CPTEG) and CPTEG:CPH copolymer 
microspheres using solid/oil/oil emulsion (left) and cryogenic atomization (right) 
fabrication techniques. Error bars indicate standard deviations. 
  
4.4.3 SDS-PAGE  
Since the release kinetics studies did not show a significant difference between the solid-
oil-oil and cryogenic fabricated microspheres, cryogenic atomized microspheres were 
used for the protein stability studies due to the ease of scale-up and the simplicity of 
fabrication. 
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Ova has a tendency to form moisture-induced covalent aggregates 39, which is shown by 
the presence of characteristic bands between 54 and 97 kDa (lane 2), in addition to the 
normal Ova band at 48kDa.  
 
The ova released from the Poly(SA), 20:80 CPH:SA, and 50:50 CPH:SA microspheres 
(lanes 3, 4, and 5, respectively) show the same higher molecular weight band as the 
unencapsulated ova (lane 2), but failed to display the bands at 45 kDa, which is the 
molecular weight of non-aggregated ova.  This indicates that the CPH:SA system fails to 
prevent non-covalent aggregation of the protein, presumably due to hydrophobic 
interactions; however, considering no bands are displayed at a lower molecular weight, it 
means these chemistries did not promote hydrolysis or degradation of the protein. This is 
consistent with the surface erodible nature of these polymers. 
 
The amphiphilic polymers (Poly(CPTEG), 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH) 
all showed normal ova bands at 45 kDa as well as the aggregated state, which are both 
observed in the unencapsulated ova.  The bands for the unaggregated ova became darker 
with an increase in CPTEG content.  Once again, no low molecular weight bands were 
present, meaning these polyanhydride chemistries did not degrade or cause hydrolysis of 
the protein. 
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Figure 4.10 – SDS-Page of ova released from microspheres over the course of 2 weeks.  
Lane 1 – Marker; lane 2 – ova at pH 10; lane 3 – Poly(SA); lane 4 – 20:80 CPH:SA; lane 
5 – 50:50 CPH:SA; lane 6 – Poly(CPTEG); lane 7 –20:80 CPTEG:CPH; lane 8 – 50:50 
CPTEG:CPH. 
 
4.4.4 Western Blot 
Figure 4.11 shows the Western blot analysis conducted on the released protein from each 
of the fabricated polyanhydride preparations.  Again, ova shows strong bands at both an 
aggregated (54 to 97 kDa) and unaggregated (45kDa) states.  Strong bands are noted for 
both states for the protein released from each of the CPTEG-containing polymers (lanes 
6-8), indicating that the protein epitopes are readily conserved, and that the protein 
structure is not perturbed.  50:50 CPH:SA preserved the epitopes at the unaggregated ova 
state, but  produced only faint bands for the aggregated protein.  Poly(SA), due to the 
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acidic nature of its degradation product, sebacic acid, degrades the protein below 
detection of the polyclonal western blot; 20:80 CPH:SA also showed a similar effect.   
 
Figure 4.11 – Polyclonal western blot of ova released from microspheres over the course 
of 2 weeks.  Lane 1 – Marker; lane 2 – ova at pH 10; lane 3 – Poly(SA); lane 4 – 20:80 
CPH:SA; lane 5 –  50:50 CPH:SA; lane 6 – Poly(CPTEG); lane 7 –20: 80 CPTEG:CPH; 
lane 8 – 50:50 CPTEG:CPH. 
 
4.5 Discussion 
As expected, the higher the hydrophobicity of the polymer, the slower the degradation 
rate, as the rate at which water penetrates into the bulk slows in correlation 40.  In regards 
to the release kinetics of ova, both fabrication methods were consistent with each other.  
Cryogenic atomization is a preferential method of preparing microspheres, due to its ease 
of scale up. Burst profiles are correlated with the polymer hydrophobicity, as the most 
hydrophobic microspheres, Poly(SA) and CPH:SA copolymers display the largest burst 
regardless of the fabrication method used.  This may be attributable to the 
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thermodynamic incompatibility of the protein with hydrophobic copolymers. Therefore, 
though the actual amount of protein released at the start of the degradation/erosion cycle 
may vary, the trend of hydrophobicity correlates with the observed burst effect.    
 
When a drug or a protein is incorporated into a microsphere, the drug/protein molecules 
may be non-uniformly distributed due to thermodynamic incompatibility with the 
polymer carrier.  Therefore, when drug-loaded microspheres immersed into a solution, 
the drug that is closer to the surface immediately escapes into the bulk solution, resulting 
in a large, instantaneous release of the drug. Microspheres fabricated with the solid/oil/oil 
emulsion method exhibited different burst characteristics than CA, with higher initial 
bursts resulting from the cryogenic atomized microspheres. This could be attributed to 
the differences in polymer precipitation and solvent extraction rate kinetics for each 
method.  For CA, for example, the polymer solution is sprayed into frozen ethanol with 
an overlaying layer of liquid nitrogen, which slows the precipitation of polymer in the 
non-solvent.  In addition, the beaker is placed in a -80 °C freezer for three days, over 
which the methylene chloride is slowly extracted into the ethanol to form and harden the 
microspheres.  Due to the slow rate kinetics of the polymer precipitation and solvent 
extraction, the protein is also extracted to the surface instead of being evenly dispersed, 
resulting in a greater burst effect.  Microspheres made by the S/O/O method may have 
more uniformly distributed protein, as the process is conducted in an ice bath, and the 
extraction occurs over 2 h.  Polymer chemistry affected both of these rate kinetics; the 
more hydrophobic the polyanhydride, the less likely these kinetics had an effect on the 
initial burst. 
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As previous studies have shown, hydrophobic polymers affect the stability of the 
protein10; and the data reported here is consistent with the literature.  Overall, these 
studies indicate that polymer chemistry affects protein stability.  The acidity of the SA 
and 20:80 CPH:SA degradation products affected both the primary structure and 
recognization of epitopes; only 50:50 CPH:SA fared better at epitope conservation at the 
unaggregated ova state.  Protein structure and epitope availability of ova was better 
maintained in microspheres fabricated using CPTEG regardless of composition of 
method.  This is likely due to the amphiphilic nature of the polymer, which has been 
shown to be conducive to protein stability 20,41.   
 
These studies are of particular importance when designing protein delivery carriers.  As 
discussed earlier, the polymer chemistry plays an important role that can be beneficial or 
detrimental for proteins.  A balance between hydrophobic and hydrophilic environment 
(i.e. amphiphilic) is necessary to ensure protein stability, as discussed elsewhere 41.  
Drugs such as insulin have important stability implications; it has been proven to undergo 
structural changes upon release from encapsulated PLGA microspheres, due to the acidic 
nature of the polymer 42.  Insulin can also undergo both covalent and noncovalent 
aggregation when introduced to moisture-rich environments 43. Uterocalin, an acute phase 
protein being investigated for therapeutic use in wound healing applications, has also 
been theorized to become biologically inactivated upon structural modification 44,45.  
Since proteins are well structured and ordered, their integrity must not be upset in order 
for it to function as intended; thus, it is imperative that the delivery device must not cause 
any disruptions to the structure.  This is especially crucial in the areas of vaccination, 
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where multi-epitope vaccines have been proven more effective than their single-epitope 
counterparts for diseases such as cancer 46 and AIDS 47; By constructing a multi-epitope 
antigen, antibodies learn to recognize all epitopes, thus becoming more effective.  In 
addition, mutation or evasion of cells is decreased dramatically; mutant epitopes can even 
be designed and introduced into the protein structure to avoid such problems 48.  
However, if the polymer delivery vehicle is not capable of preserving the availability of 
epitopes, the multi-epitope antigen is not able to deliver at its full capacity. 
 
4.6 Conclusion 
These studies established the effects of polyanhydride chemistry and microsphere 
fabrication methods on release kinetics and protein stability.  Cryogenically atomized 
polyanhydride microspheres containing CPTEG demonstrated the best preservation of 
epitopes and primary structure, thus confirming previous work done on amphiphilic 
environments being the best suited for ensuring protein stability 41.  
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CHAPTER 5 
EFFECT OF POLYMER CHEMISTRY ON IMMUNE ACTIVATION OF 
DENDRITIC CELLS 
5.1 Introduction 
Over the last 200 years, the use of vaccines has proven to be one of the most successful 
medical interventions in the reduction of disease caused by infectious agents. However, 
many challenges still remain with regard to fully realizing the health benefits of active 
immunization programs. Some of these obstacles include the implementation of 
improved adjuvants, development of single dose vaccines, methods to overcome the poor 
immunogenicity of recombinant and subunit immunogens, and the ability to rapidly and 
rationally develop vaccines against emerging pathogens. In this regard, the mechanisms 
underpinning the effective modulation of cellular and molecular events associated with 
adjuvant enhancement of immune responses is still unclear. What is well known is that 
the first step in the immune response process is the activation of antigen presenting cells 
(APCs), the most prolific of them being dendritic cells (DCs).  
 
Dendritic cells are responsible for the induction of both T and B cell mediated immune 
responses. They are found in large numbers in the lymph, spleen, skin, and bloodstream.  
Immature DCs constantly sample the surroundings for pathogens such as viruses and 
bacteria. Once they come into contact with such pathogens, they engulf the pathogen 
through phagocytosis, migrate to the lymph nodes, and undergo maturation.  Upon 
maturation, DCs present the protein fragments or antigens, which are bound to MHC 
class II molecules, on their surface; this presentation leads to a surge of class II molecule 
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production.  Consequently, CD4+ T cells recognize this MHC antigen complex, and 
activate B cells to differentiate into antibody secretingplasma cells or other T cells, such 
as cytotoxic CD8+ T cells 1-5. 
 
Naïve T cells are not activated by MHC antigen complexes alone; they also need co-
stimulatory signals expressed by APCs for initiation.  The requirement of additional co-
stimulatory signals serves to verify the type of T cell being activated, thus minimizes the 
chance for generating active T cells against self antigens.  Co-stimulatory molecules are 
upregulated on APCs following stimulation with a pathogen or pathogen mimicking 
molecules, and are not specific towards a certain antigen.  Co-stimulatory molecules 
commonly presented for T cell activation include the B7 molecules, CD80 and CD86, 
and CD40.  The B7 molecules bind to the T cell receptor CD28, and CD40 binds to the 
C40 ligand on T cells.  The binding of CD40 to the CD40 ligand is not only important for 
activation of the T cell, but also provides a necessary signal to initiate T cell proliferation 
3-5.   
 
Another important molecule recognized by DCs is the intercellular adhesion molecule 
(ICAM).  ICAM-3, in particular, is found on the surface of naïve T-cells, and has a strong 
attraction for the DC specific mannose C-type lectin of DC-SIGN (dendritic cell specific 
ICAM-3 grabbing non-integrin), designated in the mouse as CD209 3,6.  Found in high 
levels on the surface of mature DCs, DC-SIGN is also responsible for recruiting and 
trafficking resting T cells through binding of ICAM-2 and promoting T cell proliferation 
6,7. 
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Drug and protein delivery vehicles have been investigated in the past for providing a 
controlled release, parenteral delivery, and being biocompatible; biodegradable polymers, 
such as poly(D,L-lactide-co-glycolide) (PLGA), are able to provide all three.  Due to 
PLGA’s bulk-eroding properties and acidic degradation products, both of which can 
cause protein aggregation, PLGA can be considered detrimental to the protein’s structure 
and stability 8-10.   Polyanhydrides, another class of biodegradable polymers, have been 
proven superior in these areas, and can be considered viable adjuvants for vaccine 
delivery.  Polyanhydrides degrade by hydrolysis of their anhydride linkages, yielding 
dicarboxylic acids; this rate of hydrolysis can be altered based on monomer chemistry 11-
13.  Considering that the byproducts of polyanhydride degradation are less acidic than 
PLGA, there is less denaturing of proteins, thereby preserving the protein’s integrity 14.  
Polyanhydride microspheres also have the ability to provide a sustained release of 
antigen, based on their surface erodible properties as demonstrated by the predictable 
near zero-order release kinetics of proteins 15.  By changing the chemistry of the 
backbone, polyanhydrides can exhibit a wide range of release kinetics; copolymerization 
can result in tailored release kinetics for specific applications 16.  Due to their surface 
eroding nature, which allows no bulk water penetration into the polymeric device, 
proteins remain stable and not subjected to moisture induced-aggregation or hydrolysis.  
However, the possibility of non-covalent aggregation may still occur, due to the 
hydrophobic chemistry of polyanhydrides 17,18.  Therefore, work has been done to 
incorporate hydrophilic oligomeric ethylene glycol units, in particular triethylene glycol 
to polymers such as poly(carboxyphenoxy hexane) to make the polymer amphiphilic.  
These changes to the chemical structure create a more favorable environment for the 
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proteins, leading to prevention of non-covalent and covalent aggregation19.  An in vivo 
study with tetanus toxoid loaded polyanhydride microspheres by Kipper et al 
demonstrated the immunomodulatory properties of polyanhydride delivery vehicles; by 
changing the copolymer chemistry, a balanced immune response (i.e., both shift in serum 
antibody profile) was observed 20.  The ability to modulate the immune response makes 
these polyanhydride delivery vehicles versatile, especially when compared to traditional 
alum-based vaccines, which are only able to induce/enhance a TH2 (humoral) response 21.   
 
The purpose of this study was to investigate the surface marker expression of murine 
bone marrow- derived DCs by polyanhydride microspheres based on the anhydride 
monomers sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-
carboxyphenoxy)3,6-dioxaoctane (CPTEG), and study the effect of polymer chemistry on 
DC activation.  E.coli lipopolysaccharide (LPS), a microbial cell wall component known 
to activate DCs, was used as positive control 22.  The surface markers investigated 
included MHC II, DC SIGN (CD209), CD86, and CD40, all associated with DC 
maturation 3-5; statistical analysis was performed by assessing the changes in the 
percentage of CD11c+ DCs expressing a given cell surface marker as opposed to changes 
in the mean fluorescence intensity. 
 
5.2 Materials and Methods 
5.2.1 Materials 
Sebacic acid (99%) and β2-mercaptoethanol were purchased from Sigma-Aldrich (St. 
Louis, MO).  E.coli lipopolysaccharide (LPS) and rat immunoglobulin were purchased 
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from Sigma (St. Louis, MO).  Granulocyte macrophage colony stimulating factor (GM-
CSF) was purchased from PeproTech (Rocky Hill, NJ).  Unlabeled mouse IgG was 
purchased from Pharmingen (Becton Dickinson, Franklin Lakes, NJ).  Mouse serum and 
unlabeled CD36/16 FcγR was purchased from (Southern Biotech, Birmingham, AL).  
Methylene chloride was purchased from Fisher Scientific (Fairlaw, NJ).  RPMI 1640, 
7.5% sodium bicarbonate, penicillin, streptomycin, and L-glutamine were purchased 
from Mediatech (Herndon, VA).  Heat inactivated fetal calf serum was purchased from 
Valley Biomedical (Winchester, VA).  Unlabeled hamster IgG, Alexa Fluor® 700 anti-
mouse CD11c (clone N418), FITC conjugated anti mouse/rat MHC Class II (I-Ek) (clone 
14-4-4S), PE/Cy7 anti-mouse CD86 (clone GL-1), allophycocyanin (APC) anti-mouse 
CD40 (clone 1C10), PE conjugated anti-mouse CIRE (DC-SIGN 209) (clone 5H10), and 
corresponding isotypes Alexa Fluor® 700 conjugated Armenian Hamster IgG (clone 
eBio299Arm), FITC IgG2a K (clone eBM2a), PE/Cy7 conjugated rat IgG2b isotype 
(clone KLH/G2b-1-2), APC Rat IgG2a κ (clone eBR2a), and PE-conjugated rat IgG2a 
(clone eBR2a) were all purchased from eBioscience (San Diego, CA).  
 
5.2.2 Polyanhydride synthesis 
To synthesize 1,6-bis(p-carboxyphenoxy)hexane (CPH) monomer, a technique to 
produce 1,3-bis(p-carboxyphenoxy)propane was altered.  A method described by Shen 
and co-workers 23 was used to produce prepolymers of CPH and sebacic acid (SA); a 
method described by Kipper et al. 24 was used to produce copolymers of CPH and SA and 
the SA homopolymers by melt condensation.  All monomers, pre-polymers, and 
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polymers were characterized by 1H NMR spectroscopy using a Varian VXR-300 NMR to 
ensure purity. 
 
5.2.3 Microsphere fabrication and characterization 
Microspheres were fabricated by the cryogenic atomization technique, similar to a 
method previously published by Determan 25 with minor modifications.  Briefly, 100 mg 
of polymer was dissolved into an amount of methylene chloride given in Table 1 for each 
polymer.  The polymer solution was pumped over 200 mL of frozen ethanol (200 proof) 
with a  programmable syringe pump (KD Scientific, Hollison, MA), glass syringe, and 20 
gauge capillary tube and atomized by a ultrasonic atomizing nozzle (SonoTek 
Corporation, Milton, NY).  Flow rates and wattage settings for each of the polymers are 
shown in Table 1.  The liquid nitrogen was allowed to boil off over three days in an -80 
°C freezer.  The solutions was then filtered and dried overnight in a vacuum oven.  The 
resulting microspheres were imaged by a JEOL 840A scanning electron microscope 
(SEM, Tokyo, Japan), to verify spherical shape and size distribution.  
Table 5.3 – Parameters for microspheres for cryogenic atomization 
 Methylene chloride Flow rate Wattage 
Poly CPTEG 
50:50 CPTEG:CPH 
20:80 CPTEG:CPH 
7 mL 3 mL/min 1.5 W 
10:90 CPTEG:CPH 4 mL 1.5 mL/min 2.5 W 
50:50 CPH:SA 3 mL 1.5 mL/min 2.5 W 
Poly(SA) 
20:80 CPH:SA 3 mL 3 mL/min 1.5 W 
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5.2.4 Isolation and culture of dendritic cells 
A method by Lutz et al. 26 was used to obtain bone marrow DCs. Briefly, C3H/HeOuJ 
mice (ISU Laboratory Animal Resource breeding colony) were euthanized with CO2 gas 
and wet with 70% ethanol.  The femur and tibia were used to collect the DCs; bone 
cavities were washed thrice with a total of 3 mL of wash media.  Cells were centrifuged, 
racked, and plated at 4x106 cells per Petri dish with 10 mL of dendritic cell media 
consisting of RPMI 1640 supplemented with 1% L-glutamine, 1% penicillin-
streptomycin solution, 1% HEPES, 10% heat inactivated fetal calf serum, 200 µL 1:100 
dilution β2-mercaptoethanol, and 10 ng/mL granulocyte macrophage colony stimulating 
factor (GM-CSF).  Plates were incubated at 37 °C with 5% CO2.  On the third day and 
sixth days, 10 mL of warm media was added to each Petri dish to supplement DCs.  On 
the seventh day, the DCs were harvested from the Petri dish and placed in 24-well plates 
for stimulation. 
 
5.2.5 Stimulation of dendritic cells with polyanhydrides 
Polyanhydride microspheres (Poly(SA), 20:80 CPH:SA, 50:50 CPH:SA, 10:90 
CPTEG:CPH, 20:80 CPTEG:CPH, 50:50 CPTEG:CPH, and Poly(CPTEG)) were added 
to separate wells of immature DCs at concentrations of 0.25 mg/mL, which allowed for a 
cell:microsphere ratio of 6:1.  For a positive control, 200 ng/mL of LPS was added to 
stimulate immature DCs; cells were also left without stimulants to serve as a negative 
control.  Well plates were placed in the incubator at 37 °C with 5% CO2 for 48 hours. 
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5.2.6 Staining of dendritic cells 
After 48 hours of stimulation, the well plates were checked for viability visually using an 
inverted microscope.  DCs were transferred into tubes and placed in the centrifuge (2500 
rpm 5 minutes) to rid the cells of the culture media.  To ensure specific staining, 250 µL 
of flow block (100 mL FACS, 1% Rat Immunoglobulin G (IgG), 100 µL unlabeled 
hamster IgG, 100 µL unlabeled mouse IgG, 2% mouse serum, and 250 µL unlabeled 
CD36/16 FcγR) was added to each tube, and tubes were incubated at 4 °C for 1 hour.   
The antibodies specific for MHCII (.25 μg), CD86 (.24 μg), CD11c (.12 μg), CD40 (.48 
μg), and CD209 (.6 μg) were added, and the cells were incubated on ice for 1 hour; 
respective antibody and isotype controls were also prepared and added to separate 
aliquots of cells as negative controls.  Following incubation with the antibodies, cells 
were washed twice by centrifugation with cold FACS/FBS buffer (500 mL phosphate 
buffer saline, 500 mg sodium azide, 1% fetal calf serum).  Cells were resuspended in 200 
µL of FACS/FBS, and cells were run immediately on the Becton-Dickinson FACSCanto 
flow cytometer (San Jose, CA).  Propidium iodide (PI), was added just before analysis to 
differentiate live from dead cells.  Data was analyzed using FlowJo flow cytometry 
analysis software (Tree Star Inc., Ashland, OR).  
 
5.3 Results 
5.3.1 Size distribution 
Figure 5.1 demonstrates the typical size of polyanhydride microspheres used in the study; 
ideally, microspheres should be less than 10 μm, which can lead to efficient phagocytosis 
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by dendritic cells, and thus enhance presentation to immune cells 27. Figure 5.2 shows the 
percentage of microspheres that are under 10 μm for each polyanhydride formulation. 
  
  
   
Figure 5.9 – Poly(SA) (top left), 20:80 CPH:SA (top right), 20:80 CPTEG:CPH (bottom 
left) and 50:50 CPTE:CPH (bottom right) microspheres.  Scale bar for top microspheres 
represents 2 μm; for bottom microspheres, 5 μm. 
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Figure 5.10 – Percentage of microspheres smaller than 10 μm for each polyanhydride 
chemistry incubated with DCs 
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5.3.2 Assessment of surface markers by flow cytometry 
After six days in culture, bone marrow cultures proliferated from microcolonies and 
developed into semi-adherent single cells.  Many cells developed hair like-projections, 
known as dendrites, which were visible with light microscopy (Figure 5.3, left).  
Microspheres appeared to be readily phagocytosed by DCs within 24 hours after addition 
(Figure 5.3, right).  Preliminary results from companion studies have shown that 
polyanhydride microspheres are contained within these cells in a multitude of 
intracellular compartments (data not shown; manuscript forthcoming).   
  
Figure 5.3 – Unstimulated bone marrow dendritic cells (left) and after incubation with 
CPTEG:CPH microspheres (right).  The dark areas in the picture on the right are polymer 
microspheres. 
 
Flow cytometric analysis of the BMDCs revealed that 86% of cultured cells expressed 
CD11c on their cell surface (i.e., were DCs), as shown in Figure 5.4; all subsequent 
analysis were performed by gating on PI-negative,  CD11c+ population. 
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Figure 5.4 – Histogram of percent positive CD11 cells (dark line).  CD11c isotype 
control (light line) is shown for comparison. 
 
Significant shifts occurred for MHCII surface marker expression upon maturation of DCs 
with polyanhydrides.  Cells incubated in the presence of the more hydrophobic 
polyanhydrides (10:90 CPTEG:CPH, 20:80 CPTEG:CPH, 50:50:CPH:SA) exhibited two 
subpopulations, a broader and taller peak at a dimmer fluorescence, and a smaller peak at 
a higher fluorescent intensity.  For the relatively more hydrophilic polyanhydrides, only a 
narrow peak at the lower fluorescence appeared. 
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Figure 5.5 – Representative plot of MHCII surface marker expression of CD11c+ cells 
following stimulation with polyanhydrides microspheres. 
 
In the CPH:SA system, an increase in the CPH content was found to increase CD86 
surface marker expression; in the CPTEG:CPH system, an increase in CPTEG was found 
to cause the same effect. Therefore, while SA did not enhance surface marker expression, 
CPTEG proved to be exceptional at inducing this co-stimulatory molecule, achieving 
expression near that of the LPS positive control.  Poly(CPTEG) and 50:50 CPTEG:CPH, 
the two highest stimulating polyanhydrides, showed a 2.6 and 3.0 fold increase over the 
non-stimulated negative control, respectively.  The only chemistry not proficient at 
inducing stimulation of DCs was Poly(SA). 
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Figure 5.6 – Representative plot of percentage of CD11c-positive cells also expressing 
CD86 following stimulation by polyanhydride microspheres. 
 
Overall, a decrease in hydrophobicity decreases surface marker expression of CD40.  
Poly(CPTEG) and 50:50 CPTEG:CPH were adept in activating mature DC, showing a 
11.4 and 12.3 fold increase, respectively, indicating that DCs are activated by 
amphiphilic chemistries.  Even the lower expressing polymers were able to express more 
than 2.7 times that of non-stimulated cells; this indicates that polyanhydrides are 
proficient at activating co-stimulatory molecules.  
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Figure 5.7 – Representative plot of percentage of CD11c-positive cells also expressing 
CD40 following stimulation by polyanhydride microspheres. 
 
Figure 5.8 demonstrates the results of staining DCs with DC-SIGN CD209.  Once again, 
the amphiphilic chemistry was preferential in expression of DC-SIGN CD209.  The more 
amphiphilic polyanhydrides Poly(CPTEG) and 50:50 CPTEG:CPH surpassed the LPS 
positive control, both tallying more than five times that of the non-stimulated DCs, 
compared to 1.4 times for LPS. 
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Figure 5.8 – Representative plot of percentage of CD11c-positive cells also expressing 
CD209 following stimulation by polyanhydride microspheres. 
 
5.4 Discussion 
Immature dendritic cells are phagocytic in nature, and once mature, express high levels of 
MHC class II molecules, the adhesion molecule DC-SIGN, and the co-stimulatory 
molecules CD86 and CD40 3-5.  As demonstrated, all polyanhydride microspheres, 
regardless of chemistry, were shown to induce maturation of murine dendritic cells; the 
degree to which each surface marker tested was activated was a function of polymer 
chemistry.  In comparison, PLGA stimulates all the markers as well, but not to the same 
magnitude; for the MHCII, CD40, and CD209 markers, it induced the least amount of 
stimulation of all polymers tested, and enhanced only slightly more CD86 marker 
expression than 20:80 CPH:SA (Data not shown). 
 
Stimulation of DCs was enhanced with the amphiphilic chemistries, as shown by 
increased surface marker expression of co-stimulatory molecule CD40, the adhesion 
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molecule DC-SIGN, and antigen presenting MHCII molecules.  CD86 was the only 
marker to show a different response, with a trend related to hydrophobicity.  Since it has 
been shown that increase expression of CD40 also up-regulates CD86, there must be 
more than one pathway activated by these polymers since we observed enhanced 
stimulation of CD86 by some polymers without the increase in CD40 5,28,29.  Another 
observation is the high levels of surface expression of CD40 for all the DCs incubated 
with polyanhydrides ; even if high levels of MHCII and co-stimulatory molecules are 
present, the CD40-CD40L relation is still required for both CD4+ and CD8+ T cell 
immunity 30.  For MHC class II molecules, high levels were especially noted with the 
more hydrophilic molecules, nearing 90% of dendritic cells testing positive with 
Poly(CPTEG).   
 
Considering it is well known that the more hydrophobic a polymer, the more 
inflammation can occur upon implantation 31, hydrophobicity corresponds to 
immunostimulatory properties.  Inflammation also can correspond with high levels of the 
surface marker CD40 32.  All polyanhydrides-incubated DCs were able to express CD40, 
which is appropriate, since polyanhydrides are hydrophobic molecules.  What is 
interesting to note is that the molecules with more hydrophilic entities (CPTEG-
containing polymers) were actually better at expressing CD40 than the more relatively 
hydrophobic polyanhydrides. 
 
Polyanhydrides are relatively hydrophobic polymers, and as proven in the results, are 
able to stimulate dendritic cells to different degrees.  The well-known “danger signal” 
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model by Matzinger may provide some explanation as to why polyanhydrides are able to 
stimulate dendritic cells. A decade later, an extension of this model was made to include 
Janeway’s self/non-self model 33, in which the common thread of hydrophobic molecules 
activating ties both models together 34.  Therefore, once a hydrophobic molecule is 
exposed to innate cells, they become activated, seeing this exposure as a danger signal 35. 
LPS, a well known microbial immunostimulatory molecule and a positive control for 
these experiments, is one such example of this, due to its hydrophobic portions. 
Therefore, it is likely the dendritic cells are reacting to the hydrophobicity of the 
polyanhydrides primarily, and can react slightly differently based on the individual 
chemistry of each polymer tested.  Since Poly(CPTEG), the most amphiphilic tested, is 
still considered hydrophobic compared to sugars and lipids, it has a balance between the 
two environments that activates dendritic cells to a higher level than its more 
hydrophobic counterparts. 
 
The differing levels of maturation by each polyanhydride can serve a great purpose.  
Polyanhydrides such as CPTEG with high levels of each surface marker, , are able to 
induce maturation of all dendritic cells.  This makes Poly(CPTEG) a prime candidate for 
diseases that need a high levels of APC activation for overcoming immune tolerance, 
such as in cancer therapies.  However, it is unclear if the lower stimulating 
polyanhydrides are capable of inducing a similar magnitude of T cell stimulation.  A 
group of cell displaying CD86 marker with Poly(SA) incubation, for example, may not 
be the same group expressing CD209.  Or, there may be a group of cells present that are 
still immature.  Partially activated cells are adequate enough to provide a tolerance 
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against a certain disease (such as rheumatoid arthritis).  In order to achieve a desired level 
of immune activation, using a cocktail approach of various polyanhydrides may be 
desired.   
 
5.5 Conclusion 
As demonstrated, all the polyanhydride chemistries studied were shown to induce 
maturation of murine dendritic cells; the degree to which each surface marker tested was 
activated was a function of polymer chemistry.  In addition to supporting Matzinger’s 
danger model, the maturation of DCs also showed a preference for the more amphiphilic 
polyanhydrides.  Further investigation is needed to elucidate the effect of differing 
activation on T cell responses.  Taken together, polyanhydrides show considerable 
promise for a wide variety of protein delivery applications by tailoring not just the release 
kinetics, but also the level of stimulation of key antigen presenting cells. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK 
6.1 Conclusions 
The overall objective of this research is to study the effect of polyanhydride chemistry on 
protein release and stabilization and on immune cell activation. The polyanhydrides 
studied in this work are based on Poly[1,6-bis(p-carboxyphenoxy)hexane] (CPH), 
Poly(sebacic anhydride) (SA), and Poly[1,8-bis(p-carboxyphenoxy)3,6-dioxaoctane] 
(CPTEG). Ova was studied as the model protein in these studies. The two specific goals 
of this thesis are to: 
 
Specific goal 1:  Determine how polymer chemistry and fabrication methods affect the 
release kinetics of proteins from polyanhydride microspheres and the stability of the 
released protein. 
 
Specific goal 2:  Investigate the surface marker expression of murine bone marrow-
derived dendritic cells by polyanhydride microspheres and study the effect of polymer 
chemistry on activation pathways of these immune cells. 
 
Specific goal 1 was addressed in Chapter 4.  Two non-aqueous methods of ova-loaded 
polyanhydride microspheres were studied: solid/oil/oil emulsion and cryogenic 
atomization.  In addition, the stability of the released protein from cryogenic atomized 
microspheres was evaluated by SDS-PAGE and Western blot analysis to determine the 
state of the protein’s primary structure and epitope availability.  As expected, the more 
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hydrophobic polyanhydrides were shown to provide a slower release rate of Ova.  No 
significant difference was observed between the two methods.  The more amphiphilic 
polyanhydrides, i.e., those containing the CPTEG monomer, preserved both the primary 
structure and epitope availability.  Polymers containing SA were not able to preserve 
either; this is most likely attributed to the acidity of the degradation product. 
 
Specific goal 2 was investigated in Chapter 5.  The expression of the co-stimulatory  
molecules CD86 and CD40, the adhesion molecule DC SIGN, and MHCII molecule, all 
known to be expressed on mature dendritic cells, was analyzed after DCs were incubated 
with polyanhydride microspheres. All polyanhydride microspheres, regardless of 
chemistry, were shown to induce maturation of murine dendritic cells; the degree to 
which each surface marker tested was activated was a function of polymer chemistry.  
For CD40, DC-SIGN, and MHCII molecules, the stimulation of DCs increased with 
increasing hydrophilicity.  CD86 was the only marker to show a different response, with 
a trend related to chemistry rather than hydrophobicity.  Matzinger’s “danger signal” 
theory was used to describe why polyanhydrides are able to stimulate DCs 1.  Normally, 
the hydrophobic portion of molecules is not exposed in the body; instead they aggregate 
or form micelles to hide the segment.  Therefore, when a hydrophobic segment or 
molecule is uncovered, it is considered a sign of danger, and the immune system becomes 
activated.  Since polyanhydrides are relatively hydrophobic, the DCs may see them as an 
alarm signal, and thus mature.  An interesting observation is that Poly(CPTEG), the most 
amphiphilic of the polyanhydrides tested, showed the most proficiency at activating DCs; 
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therefore, a balance between the hydrophobic-hydrophilic environment must be preferred 
to activate DCs. 
 
The common thread through these two studies is that the chemistry of the polymer is of 
utmost importance when designing a protein vehicle, affecting aspects such as protein 
stability, release kinetics, and dendritic cell activation.  The amphiphilic environment 
proved to be superior to the hydrophobic chemistries in achieving these attributes.  
However, a cocktail of microspheres with different polyanhydride microspheres may be 
the most desired as it would provide control over the release rate and the burst, while also 
providing the preferred immune response. 
 
6.2 Future Work 
6.2.1 Interaction of polyanhydrides and the immune system 
As discussed in Chapter 5, different polyanhydride chemistries are capable of stimulating 
surface markers on dendritic cells (DCs) to a different degree.  Toll-like receptors, 
located on the surface of cells such as DCs, are pattern-recognition receptors; each 
receptor recognizes different molecular patters.  TLR-4, for example, recognizes the 
bacterial-derived lipopolysaccharide; TLR-2 recognizes not only LPS, but other 
microbial components such as peptidoglycans.  Recognition of these patterns aids in 
maturation of DCs and allows them to display co-stimulatory molecules essential to an 
appropriate immune response.  While polyanhydrides were found to stimulate the same 
surface markers as LPS, and in some cases surpass the performance of LPS, it is 
hypothesized that they operate through the same TLRs. 
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In addition, while surface marker expression was shown by polyanhydrides in Chapter 5, 
it is unclear as to whether it was one group of cells emitting all the surface markers or 
various cells emitting markers separately.  For polyanhydrides like CPTEG, which 
stimulated all the markers in ~90% of the cells, nearly all cells attained maturity.  For 
cells stimulated by Poly(SA), for example, it is unclear whether all the cells tested were 
mature.  Since ultimately, dendritic cell maturation will lead to T cell activation, it is 
important to actually test this by mixing T cells with the mature DCs. 
 
Ideally, microspheres should be less than 10μm, which can lead to efficient phagocytosis 
by dendritic cells, and thus effective presentation to immune cells 2.  As mentioned in 
Chapter 5, at least 60% of all microspheres incubated with dendritic cells were of 10 μm 
in diameter or less.  However, it is unclear as to whether smaller microspheres, of the 
nanometer size, would stimulate DCs to a higher level.  Therefore, nanospheres of the 
same polyanhydride chemistries tested should be incubated with DCs to determine if size 
has an effect on maturation of DCs.   Likewise, the degradation products, which are 
dicarboxylic acids, could also be responsible for stimulating DCs.  The easiest way to test 
this concept would be to set up the experiment in transwells, in which two wells 
separated by a membrane.  DCs would be placed in one well and polyanhydride 
microspheres in the second; by selecting a membrane with the appropriate pore size , 
only the degradation products of the polyanhydrides can be allowed through the 
membrane. 
 
92 
 
And finally, as mentioned throughout this thesis, is the investigation of cocktails of 
polyanhydrides.  By allowing for a mixture of polyanhydride microspheres, one can tailor 
the release kinetics, burst of protein, and immune response while ensuring protein 
stability.  Therefore, all of these past experiments should be repeated with mixtures of 
polyanhydrides with varying chemistries. 
 
6.2.2 Polyanhydride coated drug-eluting stents 
These properties of polyanhydrides also make them promising candidates for stents. 
Stents are expandable metallic mesh structures or tubes that are utilized to prevent 
occlusion, or collapse of the body’s arteries or pathways and allow blood and other flow 
to remain unrestricted 3. One dilemma with using bare metal stents is the potential for 
restenosis, or the reoccurrence of stenosis (narrowing of structure), due to tissue 
hyperplasia and the regrowth of tumors.  Another problem is the formation of neointima, 
or thick smooth muscle tissue.  Therefore, drugs are often incorporated to prevent 
stenosis, inhibit inflammation and neointima formation, and often to block cell 
proliferation and prevent thrombosis.  A variety of drugs are used in drug-eluting stents, 
depending on the application (palliative versus therapeutic, normally).  Ideally, a drug 
used should inhibit inflammation and prevent reoccurrence of stenosis, as well as block 
cell proliferation and prevent thrombosis.  Sometimes, more than one drug is 
incorporated to receive the best combination of positive activity.  Also, coating the drugs 
on the stent and applying locally requires a smaller does than would an oral or 
intravenously application.  By combining with a degradable polymer, a controlled long 
term drug release can be achieved, as when the polymer degrades over time, the drug is 
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slowly released.  The drug release can be altered simply by changing the chemistry of the 
polymer.  This also means that more drugs can be loaded onto the stent, thereby reducing 
the number of times the stent has to be replaced. 
 
At this time, there are no known polyanhydride coated stents on the market.  However, 
there are numerous patents and trials using polyanhydrides, specifically using these 
polymers as the actual stent.  These stents are termed “bioabsorbable” rather than simply 
biodegradable, implying that as the polymer degrades, cells will uptake the monomeric 
units by phagocytosis 4.  In addition to the normal characteristics of biodegradable 
polymers, bioabsorbable stents must also have excellent tensile strength to keep 
restenosis from occurring.   
 
Preliminary cytotoxicity tests were performed to determine the cellular proliferation of 
polyanhydrides with human cells, using an MTT assay with the NL-20 human bronchial 
epithelial cell line (CRL2503, American Type Culture Collection (ATCC), Manassas, 
VA); the cells were incubated overnight with 20:80 CPH:SA and 50:50 CPH:SA 
copolymers. Polymer concentrations varying from 10 mg/mL to 0.08 mg/mL were 
incubated with 6 x 105 cells/mL; the assay was run with and without cells.  Results are 
shown in Figure 6.1  For the copolymer 50:50 CPH:SA, an optical density equivalence of 
50% live was noted at a concentration of 2.5 mg/mL.  The same optical density was 
observed at a much lower concentration (0.16mg/mL) for 20:80 CPH:SA; the reason for 
the lower concentration could be attributed to the higher in 20:80 a CPH:SA.  This study 
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provides promising initial results regarding the suitability of using polyanhydrides as 
reabsorbable stents. 
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Figure 6.1 – MTT assay results 
 
Future work could include tracking the degradation of polymer over the desired time 
span, incorporation of suitable drugs into polymer matrix, additional in-vitro studies with 
epithelial cells to test biocompatibility, and finally in-vivo studies with the stent to 
confirm therapeutic value. 
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